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Abstract
X-linked inhibitor of apoptosis (XIAP) is the most potent endogenous caspase
inhibitor, preventing cell death via the caspase-9, -7 and -3 (initiator and executioner)
pathways. The project aimed to determine whether XIAP down regulation alone, or
in combination with existing therapeutic agents, is a potential treatment for patients
with colorectal cancer. Two methods of XIAP down regulation were considered;
transient knock down using antisense (AS) oligonucleotides (OGNs) and stable down
regulation by generating short hairpin RNA expressing cells.
AEG35156 (Aegera Therapeutics Inc), a 2nd generation mixed backbone AS OGN,
binds specifically to the sense XIAP mRNA strand, stimulating its breakdown and
preventing translation into protein. During its development, AEG35156 showed
efficacy in vitro in a variety of cancer cell lines. In vivo efficacy was seen in the
human colon cancer model, LS174T and synergy was seen in combination with
docetaxel in a prostate cancer model. A clinical phase I trial of AEG35156 was
undertaken in patients with advanced cancer, in Manchester and Edinburgh. The
maximum tolerated dose was 96 mg/m2/day of AEG35156, using a 7 day continuous
infusion regimen. Dose limiting toxicities were all abnormal laboratory values,
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reported at higher dose levels (125mg/m /day and 160mg/m /day).
In laboratory studies, a panel of colorectal cell lines (Colo205, HT29, SW620,
E1CT15, HCT116) have been characterised according to p53, MLH1 and XIAP
status. The HCT116 cell line is mismatch repair deficient (MLH1-) but has a normal
functioning p53. It expresses XIAP at levels similar to other members of the cell line
panel and is up regulated when compared to normal tissue. HCT116 is a well
characterised cell line which is easy to grow in vitro and as a xenograft model. It is
readily modifiable, making it a good candidate for further study.
xvii
A method of transient transfection of XIAP AS (AEG35156) in vitro was developed
which achieved 81% down regulation of XIAP mRNA using the AEG35156
compound. Down regulation of XIAP mRNA was also seen with the missense (MS)
OGN, AEG35187. Specific down regulation ofXIAP with the AS (and not MS) was
achieved using a 24 hour transfection at 400nM, but knockdown seen in this case
was only 33%. Cytotoxicity experiments showed no significant therapeutic benefit of
AS over MS. Investigation of stimulation of the extrinsic apoptotic pathway with
TRAIL following 33% XIAP down regulation did not confer a significant increase in
apoptosis when compared to the MS control. The anti-tumour efficacy and
pharmacodynamic effect of AEG35156 in vivo in a colorectal cancer xenograft
model was also investigated. AEG35156 had a significant effect on tumour growth in
the HCT116 xenograft, but a subsequent study was unable to confirm this. AS
directed against human XIAP caused target knockdown in mouse liver despite a 3
base pair mismatch, but no XIAP down regulation was seen in the human tumour
xenografts.
Using short hairpin RNA (shRNA) against XIAP, stably expressed in a parent
E1CT116 human colon cancer cell line, a series of clones were developed. XIAP
mRNA levels were established by RT-PCR, the 4 X (XIAP knockdown) clonal cell
lines showing 82-93% reduction in XIAP mRNA when compared to the 4 L
(luciferase control) cell lines. Immunoblot analysis showed a 67-89% reduction in
XIAP protein in X cell lines compared to L. Results of RNA microarray analysis of
the clonal cell lines confirmed down regulation of XIAP at early and late passage
although some of the fold change effect was lost over time. There were no
compensatory changes in genes currently documented to have an association with
XIAP function.
Therefore a colorectal cancer model has been developed using isogenic cell lines
which differ only in their XIAP status. The in vitro characterisation of these cell lines
show differences in cell growth, plating efficiency and morphology in the XIAP
deficient cell lines. The X23 cell line showed a 3-fold increase in sensitivity to
rhTRAIL. A 20% increase in sensitivity to radiotherapy was seen in the XIAP
deficient cell lines and a >2-fold increase in sensitivity to paclitaxel and docetaxel.
All 8 shRNA cell lines can be established in vivo, the L8 and X23 cell lines showing
a similar growth pattern. XIAP knockdown is maintained at the mRNA level for 26
days after implantation, though the down regulation is less than that seen in vitro.
However, treatment of X23 and L8 xenografts with docetaxel showed no significant
differential effect on growth.
Further investigation should focus on increasing the magnitude of XIAP knock






1.1 Cancer and Apoptosis Pathways
When considering strategies to eliminate malignant cells it is first important to
consider the ways in which these cells differ from healthy cells. In this way therapies
may be targeted towards differences between cancer and normal cells, thus avoiding
the elimination of normal cells. Hanahan and Weinburg (1) describe six essential
alterations in cell physiology which cancer cells develop that distinguish them from
normal cells - of which one of the most important is the ability to evade apoptosis.
Apoptosis, also described as programmed cell death, is a key regulator of
physiological growth control and normal tissue homeostasis. As a result,















Figure 1: The Apoptotic Pathway
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A complex pathway as illustrated in Figure 1 leads to apoptosis. Central to apoptosis
are the caspases - a family of cysteine proteases which trigger the apoptotic program
and dismantle the cell in an orderly fashion without inflammation. Failure to activate
caspases may account for cellular resistance to apoptosis and current treatments; this
will be discussed in more detail below.
Caspases lie in a latent (zymogen) state in cells but become activated in response to a
wide variety of cell death stimuli. This activation may broadly be divided into two
pathways - intrinsic and extrinsic - although links between them exist at different
levels (2).
The intrinsic pathway involves the mitochondrion, with caspase activation linked to
the permeability of the mitochondrial membrane. Mitochondrial permeability is
controlled by members of the B-cell lymphoma 2 (BCL2) family and the pathway is
initiated by the release of cytochrome C, second mitochondria-derived activator of
caspases/direct IAP binding protein with low pi (smac/DIABLO) and high
temperature requirement protein A2 (HtrA2) from the mitochondrion (3). Most
conventional chemotherapeutic agents including etoposide, doxorubicin, cisplatin
and paclitaxel induce mitochondrial permeability indirectly by affecting the BCL2
proteins or inducing p53 expression (4). Apoptotic protease-activating factor 1
(Apafl) binds to cytochrome C and oligomerises to form the apoptosome (5) which
triggers caspases resulting in apoptosis.
The extrinsic pathway involves the Death Receptors which are members of the TNF
(Tumour Necrosis Factor) receptor superfamily. An inducer of the extrinsic pathway
relevant to this work is TRAIL (TNF-related apoptosis-inducing ligand) which binds
to Death Receptors 4 and 5 (DR4 and DR5) (6). These are the only death receptors
with an intracellular death domain. Activation of the Death Receptors results in
cleavage of procaspase 8, the initiator caspase, which propagates apoptosis. Decoy
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receptors (DcRl and DcR2) compete for binding of TRAIL but do not have the
necessary death domain to initiate apoptosis. Therefore by regulating the expression
of DR4 and 5 and DcRl and 2 a cell may modify its response to apoptosis (7).
1.2 Colorectal Cancer and its Treatment
Colorectal cancer is the 3 rd commonest cancer in the UK (after breast and lung
cancer). There are almost 34,900 cases diagnosed in the UK each year. 13,300 of
these are in the rectum and the rest in the colon (Cancer Research UK Cancer Stats).
For patients in Scotland current guidance for the management of colorectal cancer is
produced by the Scottish Intercollegiate Guidelines Network
www.sign,ac.uk/guidelines/fulltext/67/section9 .html.
The Dukes' Staging system (Figure 2) is useful for predicting any further treatment
which may be required after surgery and also the prognosis of the patient. Five year
survival rates are 83%, 64%, 38% and 3% and the frequency of diagnosis is 11%,
35%, 26% and 29% for Dukes Stage A - D tumours respectively (taken from
http://info.cancerresearchuk.org/cancerstats/types/bowel/survival/). Therefore
approximately 20,000 people currently die each year from the disease. Advances in
clinical treatment of colorectal cancer have reduced deaths from large bowel cancer
in the UK despite increasing incidence. Between 1995 and 2004, the male age-
standardised rates fell by 16% and the female rates by 21% (taken from Cancer
Research UK CancerStats http://info.cancerresearchuk.org/cancerstats/mortality/
timetrends/). However, further development of emerging therapies and strategies to
overcome tumour resistance to current treatment regimes is required to continue the
improvement in patient survival.
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Figure 2: The Dukes' Staging System for Colorectal Cancer. Dukes' A: Tumour confined to the
mucosa. Dukes' B: Tumour infiltrating through muscle. Dukes' C: Lymph node metastasis
present. Dukes' D: Metastatic disease.
1.2.1 Cytotoxic Chemotherapy
Surgery remains the mainstay of treatment for patients with Dukes stage A and B
disease. The value of adjuvant chemotherapy for patients with Dukes B tumours is
controversial (8) and current guidelines advise discussion on an individual case basis
depending on poor prognostic risk factors (bowel obstruction, tumour adhesion,
invasion, perforation or aneuploidy). Further clinical trials are warranted to identify
which patients might benefit from current chemotherapy and novel therapeutic
strategies.
In the absence of significant co-morbidity, adjuvant chemotherapy is recommended
for patients with Dukes' C disease; there is a 4-13% increase in 5 year survival (9).
The principal chemotherapeutic agent has been intravenous 5- fluorouracil (5-FU)
but it is being increasingly replaced by capecitabine (a 5-FU prodrug) due to the
latter's tablet formulation and outpatient administration (10). 5-FU is a potent anti-
tumour agent that affects pyrimidine synthesis by inhibiting thymidylate synthase
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thus depleting intracellular dTTP pools. It is also metabolised to fluoro-
ribonucleotides and deoxyribonucleotides, which can be incorporated into RNA and
DNA. Treatment of cells with 5-FU leads to an accumulation of cells in S-phase and
has been shown to induce p53 dependent apoptosis.
More recently oxaliplatin has been added to 5-FU based regimes in the adjuvant
setting for patients with Dukes' C tumours and it is associated with increased disease
free survival in the combination therapy group (11). Oxaliplatin is a third generation
platinum compound which, unlike its parent cisplatin, is active in colorectal cancer.
Platinum compounds form adducts with cellular DNA and the type of adduct formed
with cisplatin differs from oxaliplatin (12). Oxaliplatin carries the
diaminocyclohexane (DACH) ligand which allows DNA lesions to avoid mismatch
repair and damage recognition pathways. This results in DNA strand breaks leading
to the induction of apoptosis (13). Loss of mismatch repair proteins results in low
level resistance to cisplatin but not oxaliplatin (14) and these proteins are implicated
in a subset of colorectal cancers.
Chemotherapy for metastatic disease has been shown to improve overall survival; in
a meta analysis of 5-FU based chemotherapy versus no treatment, the 1 year
mortality was significantly reduced (15). Scottish guidelines state that all patients
should be offered this treatment if medically fit. Two newer drugs irinotecan (CPT-
11) and oxaliplatin have also been evaluated in the first-line treatment of patients
with metastatic colorectal cancer. In a trial of irinotecan in addition to 5-FU folinic
acid, improvements were seen in the combination arm with increased response rate,
time to progression and overall survival (16). A randomised comparison of 5-FU and
folinic acid in combination with either oxaliplatin or irinotecan showed no difference
in overall response rate, time to progression or overall survival (17). The toxicities of
the two regimens were also similar and both are therefore licensed in the UK for use
as first line therapy in patients with metastatic disease. In Edinburgh, oxaliplatin is
preferred as it is easier to combine with capecitabine.
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Topoisomerase 1 is an enzyme which allows the DNA helix to unwind in order for a
cell to divide normally (18). Irinotecan is converted into its active form (SN-38) in-
vivo by carboxylesterase enzymes in the liver. SN-38 binds irreversibly to the DNA-
topoisomerase I complex, inhibiting the reassociation of DNA after cleavage by
topoisomerase I and traps the enzyme in a covalent linkage with DNA. The enzyme
complex is ubiquitinated and destroyed by the 26S proteasome, thus depleting
cellular topoisomerase 1. This blocks the cell cycle in S-phase at low dose and
induces apoptosis (19).
Second-line chemotherapy with irinotecan after failure of 5-FU based regimes
prolongs survival, improves symptom control and quality of life (20). The addition of
oxaliplatin to 5-FU showed no significant increase in overall survival though
response rate and time to progression were improved (21). With both drugs there
were significant increases in toxicity and therefore the current recommendation for
treatment depends on the fitness of the patient.
1.2.2 Radiotherapy
For rectal cancer, pre-operative radiotherapy with 3 or 4 fields is recommended for
local disease control in patients undergoing curative resections. Post-operative
radiotherapy may be given in cases where patients are at high risk of local relapse.
The schedule is 45 Gray (Gy) in 25 fractions over 5 weeks. Evidence from a
prospective cohort study suggests synchronous 5-FU based chemotherapy and
radiotherapy improves the complete response rate and resectability rate in more
advanced tumours and randomised Phase 3 data is awaited (22).
Radiotherapy has three roles in advanced rectal cancer; to downsize tumours to allow
attempts at curative resection, potentially curative treatment of inoperable disease,
and symptom control in persistent or locally recurrent disease. In the case of
inoperable rectal disease combined chemo-radiotherapy showed improved overall
survival in the subgroup where response to treatment and tumour downsizing
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allowed surgical intervention (23). For the palliation of symptoms in rectal cancer
44Gy in 12 fractions over 10 to 12 weeks was shown to minimize early and late toxic
effects (24) but the regimen used will vary according to centre and patient condition.
Radiotherapy damages DNA by directly or indirectly ionising the atoms which make
up the DNA chain. Indirect ionisation is more common and happens as a result of
water forming free radicals which then damage DNA. Cells have mechanisms for
repairing the DNA damage and therefore double strand DNA breaks are the most
lethal. Fractionation of approximately 2 Gy per day of the total dose allows normal
cells time to recover. Shinomiya advocates a theory of pre and post mitotic cell death
which describes two modes of apoptosis in radiation damaged cells (25). Premitotic
apoptosis is induced by high dose irradiation (20Gy), mainly occurs in the S phase
and leads to rapid apoptosis via the activation of caspase 3. Postmitotic apoptosis is
induced by low dose irradiation (5Gy), mainly occurs in the Gi phase and leads to
apoptosis after 24 hours associated with the down regulation of genes such as bcl-2
and mitogen-activated protein kinase 6 (MAPK6) which play an important role in the
mitochondrial (intrinsic) pathway of apoptosis. There is also evidence to suggest a
role for the extrinsic pathway of apoptosis in y radiation treated cells (26). Reap et al
have shown that surface Fas expression increases on normal lymphocytes exposed to
radiation and that radiation-induced apoptosis can be blocked with high
concentrations of a Fas-Fc fusion protein.
1.2.3 Targeted Antibodies in Colorectal Cancer
Cetuximab (Erbitux, Merck KGaA, Darmstadt, Germany) is a monoclonal EGFR
antibody licensed in 2004 for use as second line therapy in irinotecan resistant colon
cancer. Cunningham et al described a response rate of 23% in the irinotecan plus
cetuximab group compared to 11% in the cetuximab alone group. There were also
significant improvements in the time to progression (4.1 vs 1.5 months) in the
combination treatment group (27). Cetuximab is currently under investigation as first
line therapy in the MRC COIN study which compares continuous chemotherapy
(oxaliplatin and 5-FU) with or without cetuximab with intermittent combination
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chemotherapy. The results of the EPIC trial of irinotecan with or without cetuximab
as second line therapy in metastatic colorectal cancer were recently presented (28).
This showed a significantly longer progression free survival and higher response rate
in the cetuximab combination arm though no difference in overall survival was seen.
Currently, cetuximab is licenced as 3rd line treatment in metastatic colorectal cancer.
Bevacizumab (Avastin, Roche, Basel, Switzerland) is a monoclonal antibody against
VEGF inhibiting the angiogenesis pathway. Benefits have been shown with the
addition of bevacizumab to 5-FU/folinic acid and 5-FU/folinic acid plus irinotecan
in the first-line treatment ofmetastatic colorectal cancer (29) and therefore this drug
is licensed for first line treatment in the UK.
There are significant development costs involved with targeted agents and therefore
health care providers are increasingly seeking economic evaluation prior to the
approval of these drugs for clinical use (30). Neither of the above antibody
treatments are currently approved by the National Institute for Clinical Excellence
(NICE) and therefore are not routinely used in the UK.
1.2.4 Other agents relevant to Apoptosis
rhTRAIL (recombinant human tumour necrosis factor-related apoptosis-inducing
ligand) binds to death receptors (DR4 and DR5) on the cell surface, directly
stimulating the extrinsic apoptotic pathway. Targeting the extrinsic pathway is
attractive as most known mechanisms of resistance to chemotherapy and
radiotherapy are related to abnormalities in the intrinsic pathway (31). Monoclonal
antibodies activating the death receptors DR4 and DR5 are also in early clinical
development (32, 33). This is particularly promising for colorectal cancer as TRAIL
receptor antibodies have been shown to delay xenograft tumour growth in vivo (34).
Combinations of TRAIL pathway stimulation and an IAP antagonist would therefore
be a rational step forward in targeted therapy.
Introduction 8
Chapter 1
The taxanes (paclitaxel and docetaxel) bind to tubulin and interfere with the function
of the mitotic spindle blocking cells at the metaphase-anaphase junction (35).
Paclitaxel has also been shown to induce NFkB expression and increase levels of
XIAP in addition to other apopotic and inflammatory markers (36). These drugs are
not routinely used in the treatment of colorectal cancer; an infusion of paclitaxel
failed to show significant clinical benefit in a Phase 2 trial in patients with metastatic
disease (37). A number of resistance mechanisms to taxanes have been described,
including overexpression of the P-glycoprotein efflux pump and alterations of
assembly or stability of microtubules (38). Tortora et al (39) were able to show
sensitisation of an oral taxane with a combination of an antisense targeting protein
kinase A and an EGFR inhibitor in xenografts of colon cancer. In addition, XIAP
antisense has been shown to enhance the activity of docetaxel in prostate tumour
xenografts (40) and breast cancer RNAi XIAP cells were sensitised to taxanes (41).
In this thesis data from combination studies of taxane therapy and XIAP knockdown
in a colorectal cancer model will be described.
1.3 Apoptosis and outcome in colorectal cancer
Biomarkers are anatomic, physiologic, biochemical, or molecular parameters
associated with the presence and severity of specific disease states. They are
detectable and measurable by a variety of methods including physical examination,
laboratory assays and medical imaging. Biomarkers have been developed to identify
individuals at risk for cancer, to detect disease earlier, determine prognosis (and
potentially avoid toxic therapy), detect recurrence, predict response to therapeutic
agents and monitor response to treatment (42). Discovery, testing and validation of
tumour biomarkers markers should permit individualisation of therapy.
The development of biomarkers for routine clinical use requires a reproducible test
which is standardised, cost effective and quality controlled. Standardised specimen
collection and processing, together with measurement of physiological variation is
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essential. For routine use outside a research environment rigorous testing to set
standards is vital to ensure a high lab to lab concordance (42).
Early clues for genetic defects in colorectal cancer arose from clinical diagnostic
identification of families with hereditary colorectal cancer. Lynch and de la Chapelle
describe a theory that such cancers may be broadly divided into two groups;
proximal and distal colonic tumours (43). Proximal tumours behave in a less
aggressive manner; possess microsatellite instability and mutations in the mismatch
repair genes. Distal tumours tend to be more aggressive and have mutations of p53
(44).
An area of microsatellite instability arises during DNA replication where short
nucleotide repeat sequences (microsatellites) undergo mutation and therefore become
mis-aligned (unstable). These areas would usually be repaired by the mismatch repair
proteins, however if mutations in these repair proteins are present the defect is
allowed to persist and a tumour propagates. Deficiency in mismatch repair is
characterised by mutations of MLH1 (mutL homolog 1) in 50% and MSH2 (mutS
homolog 2) in 40% of cases of hereditary colon cancer and in 15% of sporadic cases
mismatch repair deficiencies may be identified (45).
Funaiola et al reviewed the literature for biomarkers which had prognostic
significance in early colorectal cancer and found that favourable microsatellite
instability status, as assessed by MLH1 and MSH2, correlated with better prognosis
(46). This is consistent with previously described data (44), however they did not
find a correlation with p53, BCL2 or thymidylate synthase status by
immunohistochemistry. Magrini et al described the response to irinotecan
chemotherapy in HCT116 colon cancer cell lines according to p53 and MLH1 status
which could be useful for designing rational therapies. They found that the apoptotic




Apoptosis requires a functioning p53 protein and tumours with p53 gene mutations
may display resistance to programmed cell death. p53 can be activated by a large
number of cellular stresses including DNA damage (caused by chemotherapy and
radiotherapy) which promotes apoptosis. A mutation of p53 has been shown to
correlate with poor patient survival in distal colorectal tissue samples (48) which
would agree with Lynch's theory (44). Mutations in p53 have been shown to confer
chemoresistance (49) in breast cancer. The prediction of response to chemotherapy
according to p53 status is more controversial. Ahnen et al showed that patients with
p53 over expression in colorectal tumours did not benefit from 5FU based
chemotherapy (50) however a further study was unable to confirm this (51). The role
of p53 in apoptosis is continually unfolding and increasingly complex. It does not
function in isolation therefore it is unlikely that a simple correlation with prognosis
and resistance to treatment will exist (52).
1.4 Apoptosis and Inhibitor ofApoptosis Proteins (IAP)
Apoptosis is tightly controlled and may be considered a binary life or death decision
(53). In each cell there is a balance between pro- and anti-apoptotic signals and in
cancer cells the balance is weighted towards anti-apoptosis - the cells are unable to
die. There are likely to be many mechanisms involved and no one component will be
entirely responsible for the ultimate outcome, however, if the cell is near the tipping
point of the balance it may be possible to alter one variable and allow the cell to tip
into apoptosis. In order to identify useful therapeutic targets, cells, which are
sensitive to therapy, may be compared with those which are resistant in order to
identify potential mechanisms preventing the apoptotic balance swinging in favour of
apoptosis. As shown earlier (Figure 1) apoptotic cell death relies on a caspase
controlled cascade which is tightly regulated. One of the regulatory mechanisms
identified are a family of proteins - the inhibitors of apoptosis (IAP) which have
been shown to have an important role in preventing cell death.
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The IAP family is characterised by one to three Baculovirus IAP Repeat (BIR)
domains at the NH2 terminus of the polypeptide chain (Figure 3) (54). These domains
specifically bind the functional units of caspases and allow inhibition. At present
IAPs are the only known intracellular inhibitors of apoptosis. They inhibit two
effector caspases, 3 and 7 (55) and one initiator caspase 9 (56). Caspase 9 is
responsible for the intrinsic mitochondrial death pathway (Figure 1) triggered by
chemotherapy and radiotherapy. IAPs also block the extrinsic pathway triggered by
ligands such as TRAIL and FAS binding to death receptors by inhibiting caspase 3
(the target of caspase 8).
The IAPs were first discovered in baculoviruses where it was noted that a gene
containing a zinc finger-like motif was able to regulate apoptosis (57). The
mammalian BIR domains show structural similarity to zinc fingers. Evolutionary
conservation suggests that these genes have an important role (58). Caspase
inhibition is not the only known function of these proteins, for example survivin is
known to regulate cell division (58). Some IAPs function as co-factors of signal
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Figure 3A: The Structure of IAP Family Members with alternate names. Figure 3B: XIAP
structure in detail showing the three BIR (Baculovirus IAP Repeat) domains and the sites of
caspase inhibition. CARD (CAspase Recruitment Domain). RING (Really Interesting New
Gene). Taken from the Journal of Clinical Investigation, 2005 (54).
One of the key players in the IAP family is XIAP which is the most potent known
endogenous caspase inhibitor (54). Other members of the IAP family have a role in
cellular immunity. Cellular Inhibitor of Apoptosis 2 (CIAP2) has been found to have
a critical role in the maintenance of normal innate immune inflammatory response
(61). This may be relevant in the clinical setting; a decrease in IAP could trigger an
undesirable immune response or lead to immunocompromise in a patient.
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1.5 XIAP structure and function
The XIAP gene is located on chromosome Xq25 (62) and to date no mutations or
chromosomal abnormalities have been identified implying that mutation of XIAP is
not an initiating event in the formation of cancer (54). The control of XIAP
expression is essential for a cell to be able to modulate its response to apoptotic
stimuli. A general response to cellular stress is to decrease cap-dependant protein
synthesis but XIAP is translated through an internal ribosome entry site (IRES), and
this alternative translation mechanism allows XIAP protein to be expressed under
conditions of cell stress such as serum withdrawal (63). This expression ofXIAP will
transiently protect the cell from programmed cell death and plays a role in disease
progression and resistance to therapy. The 57kDa XIAP protein contains three BIR
domains and a RING (Really Interesting New Gene) domain. The RING domain has
structural similarities to a zinc finger and is thought to provide a scaffold for
complex cellular processes (64). The functions of the XIAP domains are described
below.
1.5.1 Caspase Inhibition
XIAP inhibits caspase 3 and 7 via the linker region between BIR domains 1 and 2
(55), caspase 9 inhibition is via a hydrophobic pocket in the surface groove of the
BIR3 domain of XIAP (65). It is the most potent member of the IAP family with
caspase 3 and 7 inhibition constants of 0.2 - 0.7 nM (55). In comparison, survivin,
another member of the IAP family which contains only the BIR2 domain, has
inhibition constants of 10-20nM (66). Further experiments measuring caspase
activity by cleavage of the fluorescent compound DEVD-AFC after incubation of
recombinant caspase 3 and 7 with fragments of the XIAP protein, showed that the
BIR2 domain was sufficient to inhibit these proteases at concentrations of l-5nM
(56, 67).
Cancer cells are specifically under stress and primed for apoptosis due to genetic and
chromosomal aberrations. XIAP down regulation alone can tip the balance in favour
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of apoptosis in tumour cells suggesting that the caspases must already be active in
tumour cells compared to normal and the activity is suppressed by the IAPs (68).
Removing inhibition of caspase 3 and 7 at the distal end of the apoptotic cascade
allows these cells to undergo apoptosis (68). Thus XIAP antagonism alone may have
therapeutic effects as a single agent ethically justifying a Phase 1 clinical trial.
XIAP is characterised by its role in caspase inhibition (as described above), however,
more recently it has been found to have a role in multiple cellular events which may
contribute to its overall anti-apoptotic activity (69).
1.5.2 Ubiquitination
The functional relevance of the carboxyl terminal RING domain of XIAP is that it
shows E3 ubiquitin ligase activity. This allows XIAP to catalyse ubiquitination,
targeting proteins for degradation in the proteosome. In addition, XIAP catalyses its
own ubiquitination, a process which is dependent on the RING domain allowing
regulation of apoptosis. Stably expressed XIAP, which lacks this domain, was more
resistant to degradation implying auto-ubiquitination and degradation are key events
in apoptosis (70). The ability to activate NF-kB (Nuclear Factor-kappa B) depends
on the ubiquitin ligase activity of the RING suggesting that this occurs as a result of
ubiquitination of a regulator of the NF-kB signalling pathway.
1.5.3 Signaling Pathways
Signalling properties of XIAP can be mapped to different regions of the protein
which are not involved in caspase inhibition. This is shown by Lewis et al in
experiments where mutations in different regions of XIAP were introduced and,
although caspase inhibition was lost, the ability to activate NF-kB and JNK (Jun N-
terminal Kinase) pathways was retained (69). Ability of XIAP to participate in
signalling is an evolutionarily conserved mechanism with the regions of the molecule
required for signalling highly conserved. The role for the integration of these
functions into a single molecule remains unclear.
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NF-kB is a transcription factor which induces expression of target genes; XIAP
represents one of the NF-kB regulated genes in addition to CIAP1 and CIAP2 (71).
Many human tumours have constitutively active NF-kB which turns on the
expression of genes preventing cell death. It counteracts the apoptotic signals caused
by TNFa and thereby prevents the cell from undergoing programmed cell death.
Aggarwal et al have shown that paclitaxel induces expression of XIAP amongst
other antiapoptotic proteins via the activation of NF-kB (36). Treatment with
curcumin suppressed the expression ofNF-kB gene products in vitro and in vivo in a
breast cancer model and synergy was shown with paclitaxel. Using curcumin in
combination with paclitaxel lowers the cytotoxic dose required to be effective
therefore reducing potential toxicity (36).
JNK is a member of the MAP (Mitogen Activated Protein) kinase family which are
responsive to stress stimuli such as cytokines and involved in apoptosis. There have
been several reports ofXIAP interacting with the JNK pathway but the mechanism is
yet to be elucidated (72).
Akt is a protein kinase which is known to mediate a number of anti-apoptotic
mechanisms. The BIR1 domain ofXIAP contains an Akt phosphorylation site that is
involved in protein stabilisation (73); Akt phosphorylates XIAP protecting it from
ubiquitination and degradation. XIAP down regulation is associated with Akt
cleavage and apoptosis and has a role in cisplatin resistance in an ovarian cancer
model (74). Cisplatin decreased XIAP protein levels and induced Akt cleavage and
apoptosis in chemosensitive, but not in resistant, ovarian cancer cells.
A novel role for XIAP in copper homeostasis through MURR1 has recently been
identified (75). This was first discovered in the cells and tissues of XIAP deficient
mice (76) which were found to have reduced copper levels.
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1.6 The Endogenous Regulation ofXIAP
Multiple mechanisms exist for increasing IAP activity in a cell further adding to the
evidence for the importance of XIAP in cancer. The anti-apoptotic activity of XIAP
can be suppressed by two proteins localised to the mitochondria; smac/DIABLO (77)
and HtrA2/Omi (78). These molecules are released into the cytoplasm during
apoptosis where they bind to the same hydrophobic pocket in BIR3 which interacts
with caspase 9 (79). XIAP may bind either smac/DIABLO, Omi/HtrA2 or caspase 9
- they are mutually exclusive (80). Therefore these molecules are negative regulators
ofXIAP and can release XIAP from caspases.
XAF-1 binds to XIAP via the zinc finger region antagonising caspase activity and
causing nuclear translocation ofXIAP (81). In normal tissues levels of XAF-1 are
abundant compared to the NCI 60 panel of cancer cell lines (82). In cancer cell lines
the alteration in XIAP and XAF-1 levels may lead to increased apoptotic resistance
due to unregulated XIAP function. XAF-1 protein over expression has been shown to
induce G1 cell cycle arrest (82), consequently increased cellular proliferation may be
a direct result ofXAF-1 down regulation.
Other members of the IAP family cIAPl and cIAP2 can be shown to degrade XIAP
as they also contain RING E3 ubiquitin ligase activity (83). XIAP and cIAPl RING
domains heterodimerise and induce protein degradation. Therefore abundance of
XIAP can be regulated in a proteasome dependent manner. The RING domain of
cIAPl has a pro-apoptotic function (84); Clem et al have shown that the cleaved
RING domain is capable of killing cells in vitro. XIAP also auto-ubiquitinates (as
described in section 1.5.2) controlling its own regulation though this process is less
efficient than the heterodimerisation described between XIAP and CIAPl (83).
GSPT1/Efr3 contains a conserved four residue IAP binding motif (like smac/Diablo
and Htra2/omi) and functions as an IAP binding protein (85). In its processed form it
binds to IAPs to release them from caspases.
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1.7 Evidence forXlAP as a therapeutic target
The evidence would suggest that cancer cells use XIAP to evade extrinsic and
intrinsic cues that would normally lead to their demise. In almost all of the 60 cell
lines of the NCI panel across multiple tumour types XIAP mRNA, as quantified by
RT-PCR, is over-expressed in comparison to normal human liver (82). This has been
confirmed in an RNase protection assay (86). Elevation of XIAP has also been
detected in human malignancy including prostate (87) and colorectal tumours (88),
and AML (86) where XIAP levels were found to be increased in comparison to
adjacent normal tissue. This implies that malignant cells increase the levels ofXIAP
to avoid apoptosis. If levels could be reduced the cells would undergo programmed
cell death, either spontaneously if their caspases were activated or in response to a
cytotoxic stimulus, for example chemo- or radiotherapy.
1.7.1 Prognosis
XIAP has been identified as a useful therapeutic target by its involvement in
resistance to apoptosis (54). High XIAP levels correlate with poor prognosis
implying that a tumour is more aggressive, able to metastasise earlier or grow faster.
Human tissue from patients with pancreatic adenocarcinoma was compared to
healthy controls at the mRNA and protein levels for XIAP expression, XIAP levels
were found to be 2.1 fold higher in the malignant group which correlated with a less
favourable survival (13.4 compared to 16.1 months) (89). However, a paper by
Krajewska et al (88) was unable to correlate overall survival with XIAP in human
colorectal cancer samples by immunohistochemistry.
Increased XIAP expression correlates with poor clinical outcome in several disease
types and has been used as a prognostic indicator. In AML patients with high XIAP
protein levels had significantly poorer prognosis (86). Yamamoto et al were able to
identify an increase in XIAP mRNA levels in patients who underwent transformation
of disease from pre-leukeamic to myelodysplastic to AML and in de novo AML (90).
This suggests that up-regulation of XIAP is a mechanism for preventing cell death in
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clinical samples. However these results were not reproduced at the protein level
when assessed by immunohistochemistry.
Anoikis may be defined as apoptosis in response to detachment of an epithelial cell
from its matrix. Most epithelial cancer cells die on entering the blood stream but
tumour cells may escape this mechanism and invade other tissues. Up-regulation of
XIAP is seen in anoikis of normal intestinal epithelial cells (91) implying a transient
attempt at survival which is eventually overcome. The evidence for the role of XIAP
in the progression of colorectal cancer has been documented in clinical samples;
XIAP levels increase from adenoma to carcinoma to hepatic metastasis (92). This
implies a role for XIAP in the ability for cancer cells to metastasise from the area of
origin through the blood and a mechanism of resistance to anoikis. Increased
expression of XIAP has also been shown to contribute to anoikis resistance in a
prostate cancer model (93).
1.7.2 Resistance to Therapies
In an isogenic in vitro ovarian cancer model of A2780 and A2780cp (cisplatin
resistant) cells XIAP was found to be over expressed in the A2780cp cells and when
XIAP was down regulated with antisense the cells were sensitised to cisplatin
treatment (94). Shrikhande et al were able to demonstrate an increase in sensitivity to
gemcitabine when XIAP was silenced in two pancreatic tumour cell lines (89).
Down regulation of XIAP with antisense oligonucleotides in combination with
radiotherapy shows decreased cell survival in non-small-cell lung cancer cell lines in
vitro and in a xenograft model (95). In addition breast cancer cells expressing
shRNA to XIAP were sensitised to TRAIL (41).
These results support XIAP downregulation strategies in combination with other
therapeutic agents; cytotoxic agents or radiotherapy which stimulate the intrinsic or
extrinsic pathway. The above evidence would suggest that inhibition of XIAP
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activity would facilitate the execution of the pro-apoptotic signals when challenged
by chemotherapeutic agents.
1.8 Strategies to antagonise XIAP
Strategies that modulate the effects of XIAP may be divided into those that regulate
the amount of XIAP available and those that block its function. To date use of an
antisense oligonucleotide (OGN) is the only strategy in clinical development and this
will be discussed in more detail in Chapter 2.
1.8.1 Regulation of protein abundance
1.8.1.1 Antisense Oligonucleotides
Antisense oligonucleotides are synthetic oligonucleotides which bind in a
complementary fashion to messenger RNA and induce its degradation through
ribonuclease H (Rnase H). In order to effectively inhibit gene expression, an
antisense must be resistant to nucleases, be taken up efficiently by cells, hybridize
efficiently with the target mRNA and activate selective degradation of the target
mRNA or block its translation without causing undesirable side effects (96).
1.8.1.1.1 Antisense as a therapy
Antisense drugs are being studied in oral, intravenous, subcutaneous, intravitreal and
enema formulations in clinical trials. Fomivirsen (Vitravine™) is a licenced antiviral
drug used for the treatment of CMV retinitis in immunocompromised patients with
AIDS. The oligonucleotide is targeted against the coding region of the major
immediate-early gene of the human cytomegalovirus (97); it was the first antisense
drug, approved by the FDA in 1998 (98).
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AEG35156/GEM640 (XIAP antisense) was developed by Aegera Therapeutics Inc in
collaboration with Hybridon Inc (now Idera Pharma). It is an anti-XIAP antisense
oligonucleotide synthesised with second generation antisense chemistry. The pre¬
clinical and early clinical development will be described in Chapter 2.
1.8.1.1.2 Antisense in target validation
The mapping of the human genome unveiled an abundance of potential molecular
targets. The challenge for the pharmaceutical industry is to gain valuable insight into
the role these targets play in the body and their viability as drug targets. Ultimately,
scientists seek to understand which genes are directly involved in disease pathways
in order to develop drugs specific to key gene targets in a timely manner. This
overall task is referred to as functional genomics. Traditional drug discovery
screening methods are time-consuming, often requiring years to identify lead drug
candidates.
Antisense oligonucleotides are excellent tools in the laboratory for the identification
of gene function and help to assess whether a specific gene is a good drug target.
However, the non specific effects of phosphorothioate oligonucleotides have been
previously documented (99) and include effects on cell proliferation. Therefore it is
important to include a control oligonucleotide which is not complementary to the
mRNA of interest in laboratory studies.
1.8.1.2 Short Hairpin RNA
Short hairpin RNA (shRNA) is a short sequence of RNA that makes a tight hairpin
turn and can be used to silence gene expression. In this work a small insert encoding
a short hairpin RNA sequence targeting the gene of interest (XIAP) was cloned into
the pCDNA3 vector. The insert-containing vector was then transfected into the
colorectal cancer cell line HCT116. The insert is transcribed in the cells from a DNA
template as a single stranded RNA molecule of approximately 50 to 100 bases.
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Complementary regions spaced by a 'loop' region cause the transcript to fold back
on itself forming a 'short hairpin'. Processing by the cell's machinery converts the
shRNA into the corresponding short interfering RNA (siRNA). siRNA assembles
into RNA-induced silencing complexes (RISCs) and activates the complex by
unwinding its RNA strands. The unwound strands guide the complex to the
complementary RNA molecules where the complex cleaves and destroys the target
mRNA.
Vector based siRNA is easily transfected and the sustained repression is propagated
indefinitely (100). A stable cell line may be established which allows observation of
the long term effects of XIAP down regulation. However, construction of shRNA
may be associated with technical difficulties (101) and we are therefore grateful to
Aegera Oncology for the supply of the insert-containing vector which had previously
been validated (41).
1.8.1.3 Translational Inhibitors
Inhibitors ofXIAP translation may block the expression of the protein in cancer cells
under stress via internal ribosome entry site (IRES) based control mechanisms.
Mammalian Target of Rapamycin (mTOR) inhibitors such as sirolimus
(Rapamune™) inhibit the translation of antiapoptotic proteins including XIAP (102).
Synergy has been shown between mTOR inhibitors and dexamethasone in a multiple
myeloma model in vivo (102) and the mechanism is dependent on down regulation of
XIAP.
1.8.1.4 Compounds which Decrease Protein Half Life
Protein half life may be reduced as a further strategy for regulating the abundance of
XIAP. Akt kinase inhibitors have been shown to destabilise XIAP by leaving the
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protein hypophosphorylated and therefore more susceptible to ubiquitin-mediated
degradation (73).
1.8.2 Functional Inhibitors
Polyphenylurea compounds have been developed which antagonise the ability of
XIAP to inhibit caspase 3 (103). They bind and inhibit the BIR2 domain of XIAP
responsible for suppressing caspase 3 and 7. Karikari et al describe good in vitro and
in vivo activity in pancreatic cancer models alone and in combination with TRAIL,
radiotherapy and gemcitabine, the clinical standard of care (104).
Small molecule antagonists ofXIAP BIR3 domain (smac peptidomimetics) have also
been developed (105, 106). XIAP BIR3 domain is important for caspase 9 inhibition




1.9 Aim of the Project
The aim of this project is to determine whether XIAP down regulation alone, or in
combination with other therapeutic agents, is a potential treatment for patients with
colorectal cancer. To achieve this aim, the following studies have been undertaken
and will be discussed in this thesis.
• The characterisation of colorectal cell lines according to p53, MLH1 and
XIAP status.
• The effects of transient transfection of XIAP antisense (AEG35156) in vitro
as a method ofXIAP down regulation.
• The anti-tumour efficacy and pharmacodynamic effect of AEG35156 in vivo
in a colorectal cancer xenograft model.
• The development and characterisation of stable XIAP knock down cell lines
using short hairpin RNA.
• The in vitro response of stable XIAP knock down cell lines to therapeutic
agents.






2 Development of AEG35156
2.1 Preclinical Development ofAEG35156
AEG35156 is a second generation 19-mer oligonucleotide (OGN) in which the core
11 DNA bases are flanked by four 2'-0-methyl-modified RNA residues at the 3' and
5' ends (Figure 4).
5' - (2'-OM )4 (2'-deoxy)j, (2'-OM )4 - 3'
Exonuclease resistance RNase-H activating Exonuclease resistance
region
Figure 4: Structure of AEG35156
First generation oligonucleotides have shown dose dependant side effects of liver
transaminitis, thrombocytopenia, hyperplasia of reticuloendothelial organs,
prologation of APTT, activation of complement and renal tubular changes (107).
Second generation chemistry was developed to improve both the pharmacokinetics
and the toxicity profile of antisense compounds (107).
In second generation OGNs, the 2'-0-methyl groups introduced at the ends of the
oligos are necessary for resistance to exonucleases which cleave nucleotides from the
end of an RNA chain and therefore this aids stability of the OGN in vivo. The central
part of the oligonucleotides activates RNase H, this recognises RNA-DNA duplexes
and hydrolyses the mRNA strand thereby achieving down regulation ofXIAP.
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There has been concern regarding the immunostimulation which may arise from the
presence of CpG residues (96) and this compound was specifically optimised for
potency and specificity in the absence of CpG residues. The oligo is
phosphorothioated where the nonbridging oxygen in the normal phosphate backbone
is replaced by sulphur. The reduction of continuous length of phosphorothioate (PS)
linkages in second generation chemistry leads to improvements in the effects on
lymphocyte proliferation, thrombocytopenia, liver transaminases and renal tubular
changes (107).
The sequence of AEG35156 was selected from a screen of more than one hundred
second generation compounds. The preclinical development is fully described by
LaCasse et al (40) in work by Aegera Therapeutics Inc and will be summarised here.
2.2 Anti-tumour activity ofAEG35156 in vitro
The down regulation ofXIAP mRNA expression in vitro was seen across five human
cancer cell lines; lung, breast, pancreas, ovary and prostate. There was no colorectal
cell line included in these in vitro transfection studies. The effect was dose dependant
in 2/5 cell lines (pancreas and ovary). The EC50 was in the range 8-32nM for all five
cell lines. Of note, a reduction of up to 22% in XIAP mRNA levels was described
with the non-sense control AEG35185 indicating a non specific effect of the OGN.
RNase H assays were performed and showed the specific degradation of XIAP
mRNA from total cellular RNA in comparison to GAPDH and cIAPl mRNA which
remained intact. In pancreatic carcinoma cells (Panel) a synergistic effect of XIAP
down regulation by antisense was seen with TRAIL when neither of these agents had
an effect on cell survival alone. This effect was associated with loss ofXIAP protein
and increased PARP cleavage.
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AEG35156 was found to have anti tumour effects as a single agent in a xenograft
model of human colon cancer (LS174T). This effect was dose dependent with 60%
reduction in tumour volume relative to saline control seen at a dose of 25mg/kg/dx5
for 3 weeks. In a prostate cancer model (PC-3) a similar effect was seen though not
in a lung model (H460). However, in the H460 model, synergy was seen with
docetaxel and XIAP protein knockdown identified in the xenografts using
immunohistochemistry. In the prostate cancer model the most impressive example of
synergy was seen in combination with docetaxel. Complete regression of the
xenografts was seen and after cessation of treatment the re-growth was minimal.
2.4 Preclinical toxicology ofAEG35156
Body weight loss was measured as a sign of toxicity and <10% was seen after
prolonged exposure to AEG35156 but was non specific in that the control
oligonucleotides showed greater loss. Body weight recovered after the treatment
phase.
The immunostimulatory effect was assessed by spleen weight measurements and
compared to an 18-mer CpG oligonucleotide control. There was a 6% increase in
spleen weight in the AEG35156 group relative to the saline controls which was
found to be insignificant; the CpG treated group showed an 82% increase in spleen
weight.
On the basis of the above in vitro and in vivo data a Phase 1 clinical trial was
proposed to investigate AEG35156 as a single agent.
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2.5 Phase 1 clinical trial AEG35156
2.5.1 Introduction
XIAP antisense (AEG35156) entered Phase 1 clinical trial in March 2004. The trial
was conducted under the auspices of Cancer Research UK and two centres
participated: Christie Hospital Manchester (Prof M Ranson, Principal Investigator)
and Edinburgh Cancer Centre (Prof D Jodrell, Principal Investigator). As a Clinical
Research Fellow, I was responsible for the management of the patients in Edinburgh
and I am grateful to Prof M. Ranson and Cancer Research UK for allowing me to
discuss data from patients entered in Manchester. Patients 05, 08, 10, 11, 12, 17 (not
treated, replaced) 18, 22 and 24, a total of eight patients, were treated in Edinburgh.
The preliminary results of this trial were reported at AACR-NCI-EORTC
International Conference Molecular Targets and Cancer Therapeutics Nov 2005
(108) and ASCO Annual Meeting 2006 (109). The primary objectives were to
establish the safety and toxicity profile, the dose limiting toxicity of AEG35156 and
to establish the maximum tolerated dose (MTD) in order to propose a safe dose for
Phase II evaluation. The secondary objectives were to determine the pharmacokinetic
and pharmacodynamic properties and document potential anti-tumour activity.
Although not included in the objectives of this Phase I Trial, clearly the data accrued
will be useful in developing combination protocols with cytotoxic agents. The data
presented here are taken from the study report prepared by the CRUK Drug




Dose levels were selected based on data from regulatory pre-clinical studies in
primates utilising the same route of administration and dosing schedule. The starting
2 #dose of 48mg/m /day selected for this study was one tenth of the maximum tolerated
dose (MTD) observed in primate pre-clinical studies (480mg/m2/day), thus allowing
a margin of safety.
The schedule was based on the consideration of tissue sequestration and the two
week tissue half-life of the study drug (personal communication, Aegera
Therapeutics Inc). The seven day continuous infusion schedule was designed to
address the toxicity associated with high plasma levels of antisense agents with short
infusion regimens. The study schedule was aimed at minimising plasma levels whilst
achieving therapeutic levels ofAEG35156/GEM640.
The drug was administered as a 7 day continuous intravenous infusion every 3 weeks
at dose levels of 48, 96, 125 and 160 mg/m2/day. Single patient cohorts were treated
until a toxicity of grade 2 or higher was observed, the cohort was then expanded to 3-
6 patients per dose level. The MTD was defined as the dose level below that at which
more than 30% of the cohort developed a dose limiting toxicity (DLT). DLT was
defined as grade 3 or 4 non-haematologic toxicity, grade 4 thrombocytopenia or
grade 3 thrombocytopenia for 7 or more days or associated with bleeding, grade 3
anaemia or grade 4 neutropenia, drug related death or increase in complement levels
greater than twice baseline. Toxicity was assessed weekly and graded according to
common toxicity criteria (CTC) version 2.0. Safety was assessed through adverse
events (AE), serious adverse events (SAE), DLT, abnormal laboratory findings,
deaths, study withdrawals due to toxicity and changes in vital signs. Tumour
assessments were determined using the response evaluation criteria in solid tumours
(RECIST) criteria. Tumour response results were compiled on all patients evaluable
in terms of overall response, time to progression and survival.
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Samples were taken for pharmacokinetic (PK) and pharmacodynamic (PD) markers
during cycle 1. Aegera Therapeutics Inc performed PK and RT-PCR assays, the
Paterson Institute for Cancer Research (Manchester) was responsible for the
M30/M65 assay, the XIAP IHC method was developed by Aegera Therapeutics Inc
and validated by the Paterson Institute.
Pharmacokinetic samples were taken at 3, 6, 24, 72, and 168 hours after the start of
infusion and at 0.5, 1, 1.5, 2, 4, 6 and 24 hours after the end of infusion. The plasma
was analysed for levels of drug and major metabolites using capillary gel
electrophoresis.
PD assessments included mRNA knockdown of XIAP by RT-PCR in peripheral
blood lymphocytes (a surrogate marker) and circulating tumour cells (NHL patients)
and paired tumour biopsies were sought at the predicted MTD. In addition serial
M30/M65 cytokeratin 18, a marker of apoptosis, was assessed in patients with





In total 24 patients were enrolled in the Phase 1 trial between March 2004 and July
2006. The safety population consisted of 22 patients, as a result of two patients (17
and 19) at the 125mg/m"/day dose level, being excluded as treatment with the study
drug was not commenced.
All 22 treated patients completed the first cycle. Two patients (patients 8 and 22)
only completed one cycle. Ten patients completed two cycles of study drug and a
further ten patients completed three cycles. No patients received treatment beyond
Cycle 3, as all patients had withdrawn from the study.
The primary reason for discontinuation was disease progression (16 patients).
Although one patient withdrew consent, there was also documented evidence of
disease progression. Two patients were withdrawn from the study by the
Investigator, and again there was evidence that the decision was based on
deterioration of the patient's condition. Therefore a total of 19 patients withdrew as a
result of their underlying disease (Table 1).
Three patients withdrew from the study due to toxicity. Two patients experienced
persistent transaminitis and ALT elevations which were associated with study drug
treatment. One patient experienced a pulmonary embolism which was reported as a
SAE, and was considered unlikely to be related to study drug.
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48 96 125 160 Overall
mg/m2/day mg/m2/day mg/m2/dayd mg/m2/day (N=22)
(N=l) (N=3) (N=12) (N=6)
Progressive 1 3 8 4 16
Disease
Unacceptable 0 0 2 1 3
Toxicity
Requirement for > 0 0 0 0 0
1 dose level
reduction
Slow recovery 0 0 0 0 0
from toxicity
requiring > 2 week
delay
Patient Request/ 0 0 la 0 1
Consent
Physician decision 0 0 lb lc 2
Patient non¬ 0 0 0 0 0
compliance
Administrative 0 0 0 0 0
decision
a) Patient 24 withdrew consent but had documented disease progression
b) Documented clinical progression confirmed as the reason for Investigator withdrawing patient
c) Patient too unwell to continue and related to underlying disease
d) Patients 17 and 19 did not receive study drug
Table 1: Reason for Treatment Discontinuation (Safety Population)
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All patients experienced at least one treatment emergent AE during the study. The
most common treatment emergent AEs were abnormal laboratory values, including
anaemia (16 patients), raised AST (15 patients), raised ALT (14 patients),
lymphocytopenia (14 patients), raised GGT (12 patients), thrombocytopenia (12
patients), hyponatraemia (ten patients) and raised urea (ten patients).
The most common non-laboratory events included fatigue (15 patients), nausea (11
patients) and anorexia (11 patients). The majority of AEs reported were mild to
moderate (grade 1 or 2) in severity. Adverse events were more commonly reported in
the two higher dose levels (doses 125mg/m2/day and 160mg/m2/day).
All grade 3/4 events reported were grade 3 severities, with the exception of two AEs
(raised ALT - patient 7 and hypophosphataemia - patient 16). All grade 3 and 4
events were abnormal laboratory values. Considering the overall incidence of these
AEs (all grades), the proportion of grade 3 and 4 events were small in relation to the
overall population. Hypophosphataemia was the only abnormality where all drug-
related events reported were considered to be grade 3 or 4 in severity. Grade 3 and 4
events were reported only in the higher dose levels (125mg/m /day and
160mg/m /day). No grade 3 or 4 drug-related AE was reported in the lower dose
2 2levels (48mg/m /day and 96mg/m /day).
The most common grade 3/4 non-haematological DLT was raised ALT, followed by
hypophosphataemia, raised AST, raised GGT and raised alkaline phosphatase. All
these events were abnormal laboratory values and are consistent with the AEs
reported in this study (Table 2).
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Dose limiting toxicities were reported primarily in the higher dose levels
9 9
(125mg/m /day and 160mg/m /day), and were identified in 33% of patients receiving
2 2

















Ptsa Eveb Pts Eve Pts Eve Pts Eve Pts Eve
Raised AST 0 0 0 0 1 1 1 1 2 2
Raised ALT 0 0 0 0 2 2 2C 2 4 4
Raised GGT 0 0 0 0 1 1 1 1 2 2
Reduced Platelets 0 0 0 0 1 2 2 2 3 4
Reduced
Lymphocytes
0 0 0 0 0 0 1 1 1 1
Raised Alkaline
Phosphatase
0 0 0 0 1 1 0 0 1 1
Elypophosphataemia 0 0 0 0 lc 5 1 1 2 6
a) Patients were counted once only for each symptom AE
b) Events reflect the number of individual AE reported
c) Two AEs were grade 4 events (raised ALT - patient 7 and hypophosphataemia - patient 16)
Table 2: Treatment Emergent Adverse Event Related to Study Drug in All Patients (Grade 3/4)
The MTD was therefore identified as 96mg/m2/day of AEG35156/GEM640 under




Response 48 96 125 160 Overall
mg/m2/day mg/m2/daya mg/m2/daya'c'd mg/m2/daya
(N=22)
(N=l) (N=3) (N=12) (N=6)
Target PR 0 0 1 0 1
Lesions
SD 0 2 3 6 11
PD 1 1 1 3 6
Non- NC 0 1 4 3 8
Target PD 1 2 1 5 9
Lesionsb
New Yes 1 2 le 5 9
Lesions
No 0 1 4 4 9
Overall PR 0 0 0 0 0
Response SD 0 1 3 4 8
PD 1 2 2 5 10
NE 0 0 2 1 3
PR - Partial Response, SD - Stable Disease, PD - Progressive Disease, NC - No Change, NE - Not Evaluable
a) Patients 3,5,6,7,9,11,12,14 completed only two cycles
b) Patients 11 and 13 were not assessed in terms of non-target lesions
c) Patients 20 and 24 only had baseline scans performed
d) Patients 17 and 19 were not evaluable for tumour response as no study treatment was commenced
e) Although a three month scan for patient 20 was not performed, a skin nodule was recorded as a new lesion
Table 3: Tumour Responses According to RECIST Criteria (Efficacy Population)
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Overall, eight patients reported stable disease; ten patients reported progressive
disease and three patients were non-evaluable. However, when comparing responses
between the dose levels, there is a clear increase in the number of patients reporting
stable disease as the dose levels rise (Table 3). The majority of stable diseases
9 9
recorded were in dose levels 125mg/m /day and 160mg/m /day (three and four
patients respectively).
The CT scan of the abdomen for a patient 10 with refractory stage 4 breast cancer is
shown in Figure 5 where a response to AEG35156 in the liver lesions is clearly seen.
Unfortunately this was not sustained and the disease progressed within 28 days.
However treatment had been delayed over this 4 week period due to persistent
abnormalities in the liver function tests.
Sept 2004 Dec 2004 Jan 2005
Pre Treatment Post Cycle 3 28 days later
Figure 5: CT scan of the abdomen for Patient 10 with refractory Stage 4 breast cancer. The
liver metastases exhibited a partial response of short duration.
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In addition to patient 10, there were three patients that reported mixed responses, in
terms of areas of tumour response combined with areas of progressive disease. One
patient (Number 16) with refractory low grade non-Hodgkins lymphoma had
repeated marked reductions in circulating lymphoma cells (Figure 6) implying a
response to treatment with AEG35156.
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Figure 6: Circulating blast counts in Patient 16 with refractory low grade non-Hodgkins
lymphoma and correlation with XIAP mRNA levels
One patient with colorectal cancer was included in the study and reported disease




Steady state plasma concentrations of AEG35156 were approximately dose
proportional and were reached rapidly (within 6 hours) after the start of the infusion
(Figure 7).
I I I I I I




Figure 7: Plasma Concentrations of AEG35156 over time
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2.5.3.4 Pharmacodynamic and Mechanistic Data
In this study the relationship between pharmacodynamic markers and AEG35156
was sought so that the optimal biological dose could be established for further
studies. The aim was to evaluate XIAP inhibition and apoptosis in tumour biopsies or
circulating tumour cells, and XIAP knockdown in peripheral blood mononuclear
cells (PBMC). Also, M30/M65 cytokeratin 18 levels were used as a surrogate marker
in plasma of patients with epithelial tumours (110).
9 • •
XIAP mRNA knockdown of 82% at 125mg/m /day (Figure 6), was identified in
patient 16 which coincides with the apparent clinical response to AEG35156. In the
same patient cleaved poly ADP ribose polymerase (PARP) and active caspase 3 were
associated with reduced XIAP levels in lymphocytes (Figure 8).
Decreased XIAP and Increased Apoptosis in
Lymphocytes from Pt 16 by Flow Cytometry
□ XIAP
■ Cleaved PARP
□ Active Caspase 3
Day 1 (Pre -Infusion) Day 3 Day 7 (End Infusion)
Treatment Day (Cycle 3)
Day 15
Figure 8: Levels of XIAP, cleaved PARP and active caspase 3 in patient 16 with refractory non-
Hodgkins lymphoma during treatment with AEG35156
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An immunohistochemistry assay was also developed during the study (Figure 9)
which confirmed XIAP knockdown after treatment with AEG35156 in a patient with
refractory breast cancer (Patient 20).










Figure 9: XIAP levels in tissue by immunohistoctiemistry before and after treatment with
AEG35156 in a patient with breast cancer.
In some of the patients there was evidence of XIAP knockdown at the RNA and
protein levels as shown in Figure 6 and Figure 9. The markers of apoptosis PARP
cleavage and caspase activity were demonstrated (Figure 8) and these data correlate




This was a phase I, open-label study investigating the safety and tolerability of
AEG35156/GEM640, administered over a seven day continuous infusion period in
patients with advanced cancer.
Examination of the safety data revealed no major safety concerns associated with the
seven day continuous infusion regimen of AEG35156. The most common study
drug-related adverse events were liver function test abnormalities (ALT and AST)
and were generally mild to moderate in severity. In common with the grade 3/4
• 9
toxicities, these events tended to occur at the higher dose levels (125mg/m /day and
2 • •
160mg/m /day). Two patients withdrew from the study as a result of persistent raised
ALT and transaminitis. Approximately 30% of patients reported serious adverse
events (SAE), only two SAEs were considered to be study drug-related (pneumonia
and transaminitis) and no deaths were attributed to the study drug.
Approximately 30% of patients (seven) reported DLTs, of whom 3 continued on
treatment after dose reduction. DLTs occurred in the two higher dose levels
9 9 9
(125mg/m /day and 160mg/m /day), however one patient (125mg/m /day) who was
2 2dose reduced to 48mg/m /day and re-escalated to 96mg/m /day did experience DLTs
at these lower dose levels.
The dose limiting toxicity of liver transaminitis has been reported previously, as
early as 1997, in rat toxicology studies (111) and in 2003 (112) in a Phase 1 clinical
trial of antisense directed against Protein Kinase A. It is thought to be a class effect
of the backbone of the drug, the mechanism of which remains unexplained but it
occurs as a late effect due to tissue accumulation.
Tumour responses (defined as tumour stabilisation according to the RECIST criteria)
were reported in 36% of the patients (eight patients). There was clear evidence that a
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higher percentage of patients achieved tumour stabilisation with the 125mg/m2/day
and 160mg/m /day dose. There was also evidence of mixed responses in terms of
areas of responding tumour and areas of progressive tumour.
Pharmacokinetic studies showed that the oligonucleotides reached steady state within
6 hours in the clinical trial which is consistent with the PK studies performed in
primates (113). A Phase 1 trial of bcl-2 Antisense (G3139, Genta Inc) in Non-
Hodgkin's Lymphoma also showed a linear correlation between plasma steady state
concentration and dose (114) which is consistent with the data described here for
AEG35156.
XIAP down regulation was demonstrated at the mRNA level by RT-PCR and protein
level by flow cytometry and immunohistochemistry. That the mechanism of action
was apoptosis was demonstrated by corresponding increases in cleaved PARP and
active caspase 3. During the validation of RT-PCR technique, significant baseline
variability (Day -5 and Day -7) in XIAP mRNA levels was noted in the pre-dose
samples (115). This was thought to be due to day to day variation in the XIAP levels
of PBMCs. Therefore although RT-PCR is a very accurate technique its usefulness as
a biomarker is less obvious. It may be more useful to document a trend for each
patient determined by frequent measurements during treatment rather than




Administration of AEG35156 as a continuous intravenous infusion over seven days
in patients with advanced cancer was found to be safe. All grade 3/4 adverse events
were abnormal laboratory values; raised AST, ALT, GGT, alkaline phosphatase,
thrombocytopenia, lymphopenia and hypophosphataemia. Grade 3/4 events were
2 2
only reported at the higher dose levels (125mg/m/day and 160mg/m /day). The
MTD for this study has been identified as 96mg/m /day, as a result of the DLTs
9 9
observed at doses 125mg/m /day and 160mg/m /day. Both these dose levels caused
DLTs in more than 30% of the patient population.
Evidence of anti tumour activity was observed in eight patients, who achieved stable
disease. Ten patients were classified as progressive disease. There was evidence of
mixed responses in terms of areas of tumour response (shrinking or stabilisation)
combined with areas of progressive disease. There was a clear trend in terms of
patients with stable disease at the two higher dose levels (125mg/m /day and
9 9
160mg/m /day). The MTD was defined as 96mg/m /day: below the dose levels
where stable disease was identified. Therefore it would be important to assess
whether this dose level was associated with PD effects before pursuing the dose level
in either single agent or combination phase II studies. Data from the phase I three
day continuous infusion regimen are awaited.
Further Phase 1 clinical trials of AEG35156 are ongoing in combination with
docetaxel in solid tumours (NCIC) and idarubicin & cytarabine in AML (MD
Anderson). In the UK, studies using a shorter (2 hour infusion) are also ongoing,





3 Materials and Methods
3.1 Chemicals and antibodies
All chemicals are from Sigma-Aldrich (Gillingham, UK) unless otherwise stated.
Primary mouse monoclonal antibodies at the following dilutions were used; XIAP
(AAM-050) Stressgen (Ann Arbor, Michigan, USA) 1:1000, MLH1 (554073) BD
PharMingen (BD Europe, Belgium) 1:250, p53 (OP43) Calbiochem (San Diego,
California, USA) 1:200. Membranes were also blotted against mouse p-actin
antibody (CP01) Merck Biosciences (Nottingham, UK) at a 1:120000 dilution as
loading control. Horseradish peroxidase-conjugated secondary antibodies are from
Autogen Bioclear UK Ltd (anti-mouse) and Merck Biosciences Ltd (P-actin)
respectively.
3.2 Therapeutic agents
Recombinant Human TRAIL/TNSF10 (R&D systems, Minneapolis, USA Cat no
375-TEC) was reconstituted in sterile PBS containing 0.1% bovine serum albumin to
a stock concentration of 20pg/ml according to manufacturers instructions, aliquoted
and stored at -20°C. The following therapeutic drugs were obtained from the
manufacturers: Camptothecin (C9911), 5FU (F6627), Paclitaxel 6mg/ml (Taxol,
Bristol-Myers Squibb, New York, USA), Docetaxel lOmg/ml stored in aliquots at -
20°C (Taxotere, Sanofi-Aventis, Paris, France), Irinotecan 100mg/5ml (Campto,
Sanofi-Aventis), Cisplatin lmg/ml (Faulding Pharmaceuticals Pic, Leamington Spa,
Warwickshire, UK), Oxaliplatin (Sanofi-Sythelabo Research, Great Valley, PA,
USA), Doxorubicin 2mg/ml (Adriamycin, Pharmacia &Upjohn, Kalamazoo, MI,
USA). AEG35156 (XIAP Antisense) and AEG35187 (Missense Control) were
provided by Aegera Therapeutics (Montreal, Quebec, Canada) and were stored as a
powder at -20°C and prior to use reconstituted with PBS (subsequently normal




HCT116, HT29, SW620, HCT15 and COLO205 cells were obtained from the
American Type Culture Collection (Rockville, MD, USA) and grown in RPMI 1640
containing 2mM glutamine, 5% foetal calf serum and 1% penicillin G/streptomycin
(Invitrogen, Paisley, UK). Cell cultures were incubated in the presence of 5% CO2 at
37°C in a humidified atmosphere and split once a week using trypsin/EDTA
(0.05%/0.02%). G418 (geneticin, Invitrogen) 50mg/ml was used to select and
maintain the vector expressing cells at a 1 in 50 dilution.
3.4 Generation of stable XIAP shRNA HCT116 cells
The XIAP shRNA plasmid constructs were provided by Aegera Oncology according
to the method described in (41) using a pCDNA3 vector containing a U6 promoter. 4
x 106 HCT116 cells were plated in 100mm plates overnight prior to a 24 hour
transfection with 1 pg of pCDNA_U6_luc (L prefix clones) or pCDNA_U6_shXIAP
(X prefix clones) using Effectene (Qiagen, Crawley, UK) according to manufacturers
protocol. The next day cells were trypsinised, a single cell suspension created and
split 1:5 in 100mm Petri dishes. Geneticin was added to select vector containing
colonies and media was changed after 3 days. After 10 days colonies were seen by
eye, 24 of each X and L were picked, transferred to 24 well plates and allowed to
proliferate in the presence of geneticin. Cells were passaged when nearing
confluence and total RNA extracted to confirm XIAP knockdown at early passage
(p4) and late passage (p8).
3.5 RNA extraction
Total RNA was extracted from cells in the exponential growth phase using Tri-
Reagent according to manufacturer's instructions. All samples were DNase treated to
avoid DNA contamination of samples for RT-PCR. Initial experiments used 20U of
grade I DNase (Roche Applied Science, Indianapolis, USA) in the presence of 50U
RNase inhibitor (Roche Applied Science) at 37°C for 60min. RNA was recovered
Methods 45
Chapter 3
after phenol/chloroform and chloroform extractions followed by precipitation with
3M sodium acetate/absolute ethanol. Later experiments used TURBO DNase
(Ambion, Applied Biosystems, Foster City, CA, USA) to avoid phenol/chloroform
extractions and increase yield. RNA was dissolved in water and concentration
determined by spectrometry at 260 and 280nm. For extraction from tissue, samples
were removed from -80°C storage and quickly cut to weigh less than lOOmg. 1ml
TRI reagent was added, tissue was dismembrated for lmin at 1800rpm and extraction
continued as above. The quality of RNA extracted from tissue was evaluated by
electrophoretic analysis on a 2100 Agilent bioanalyser (Agilent Technologies, Santa
Clara, CA, USA).
3.6 Primer Design
Primers for quantitative RT-PCR were designed with Primer 3 software
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi/) using the mRNA
sequence of the genes of interest deposited at the National Centre for Biotechnology
Information (http:Avww.ncbi.nlm.nih.gov/). The mRNA accession numbers were
XIAP (BIRC4) NM_001167, cIAPl (BIRC2) NM_001166, cIAP2 (BIRC3)
NM_001165 and NM_182962, survivin (BIRC5) NM_001012270, NM_001012271
and NM_001168, XAF1 (BIRC4BP) NM_017523.2 and NMJ99139.1, mouse
XIAP NM_009688. Where more than one transcript was identified the primers were
designed against a region of high homology using the Basic Local Alignment Tool
(http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi) to align sequences. Design
criteria were the following: primer size of 18-22 bp, Tm between 57 and 63°C, GC
content 45-55%, amplicon size 150-250 bp. Primer-dimer formation was minimised
by setting the maximum 3' self complementarity to a value of 3. Primer specificity




All transcripts were detected using QuantiTect SYBR Green RT-PCR kits (Qiagen).
The reaction was carried out with lOng total RNA per reaction and primers at a
concentration of 20pM in a final volume of 15ul on a Rotor-Gene 3000 real-time
DNA detection system (Corbett Research). Each standard and sample was performed
in triplicate. Standard curves were built by serially diluting HCT116 RNA stock
solution (200ng/ul) in water to a concentration of 0.5 - 50ng total RNA per reaction.
For XAF1 expression, COLO205 was used as a standard as the gene levels were
highly expressed (lOOng for XAF1). Cycling conditions were 50°C for 30min, 95°C
for 15min, followed by 45 PCR cycles at 94°C for 15sec (denaturation), 55°C for
30sec (annealing) and 72°C for 45sec (extension). Fluorescence was recorded on the
FAM channel (Ex=470nm, Em=510nm) at the end of extension. Results were
expressed as normalised fluorescence and data analysed using Rotorgene 6 software.
A dynamic tube normalisation was used for each sample and the amplification
reaction considered an exponential process. POFR2A (RNA polymerase II subunit
A, RPII) was selected as the housekeeping gene for normalisation of the qRT-PCR
data as minimal variation was seen across cell lines (116). For experiments where
comparisons are made with microarray data, results are expressed per ng of total
RNA relative to the HCT116 parental cell line.
3.8 Detection ofprotein by Immunoblotting
4 x 106 cells from in vitro studies were washed with PBS and suspended in lysis
buffer (62.5mM Tris pH 6.8, 6M urea, 10% glycerol, 2% SDS) prior to sonication on
ice. Protein quantitation was performed using the bicinchoninic acid (BCA) assay.
25 pg protein was incubated with denaturing buffer (0.3M Tris pH 6.8, 10% 2-
mercaptoethanol, 40% glycerol, 20% SDS, 0.02% bromophenol blue) for 5 min at
95°C. Samples were loaded onto a 10% SDS-polyacrylamide gel for electrophoresis
at 60mA for 30mins then 35mA for 3-4 hours, full range rainbow molecular weight
marker was also loaded (GE Healthcare, Bucks, UK). Proteins were transferred at
28V overnight at 4°C onto polyvinylidene fluoride membranes (Hybond-P, GE
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Healthcare, Bucks, UK) and Ponceau stain performed to visualise proteins.
Membranes were blocked in 5% non-fat milk TBS-Tween for 1 hour at room
temperature and incubated overnight at 4°C in a primary antibody diluted in 2.5%
non-fat milk. Membranes were then washed in TBS-Tween, and horseradish
peroxidase-conjugated secondary antibodies incubated for 1 hour at room
temperature and washed again. Immunoreactivity was detected using the Enhanced
ChemiLuminescence Plus detection reagent (GE Healthcare) visualised on the Storm
840 Scanner (Amersham Biosciences). Protein quantification was performed with
Image Quant version 5.2 software.
3.9 Microarray
RNA from the parental cell line HCT116 (in duplicate) and vector expressing cell
lines X6, X10, X16, X23 (X) and L8, L15, L23, L24 (L) at an early passage (p4) and
later passage (p8) were analysed by microarray. Total RNA was DNase treated to
remove genomic DNA as described above and cleaned using the RNeasy mini kit
(Qiagen) to remove organic solvents. RNA integrity was checked by Agilent
bioanalyser and confirmed to be good quality. 5pg total RNA (minimum
concentration 0.6pg/ul) was sent to the Patterson Institute for Cancer Research for
microarray analysis.
The methods below are taken from the Paterson Institute for Cancer Research
Website and URL and are included where appropriate. Samples were labelled using
the Affymetrix One Cycle Target labelling Kit. All experiments were performed
using Affymetrix HGJU133 plus 2.0 oligonucleotide arrays, as described at
http://www.affymetrix.com/products/arrays/specific/hgul 33plus.affx. Total RNA
from each sample was used to prepare biotinylated target RNA, with minor
modifications from the manufacturer's recommendations
(http ://www.affymetrix.com/support/technical/manual/expression_manual.affx).
Briefly, 10 pg of mRNA was used to generate first-strand cDNA by using a T7-
linked oligo (dT) primer. After second-strand synthesis, in vitro transcription was
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performed with biotinylated UTP and CTP (Enzo Diagnostics), resulting in
approximately 100-fold amplification ofRNA. A complete description of procedures
is available at http://bioinf.picr.man.ac.uk/mbcf/downloads/ GeneChip_Target_
Prep_Protocol_CRUK_v_2.pdf. The target cDNA generated from each sample was
processed as per manufacturer's recommendation using an Affymetrix GeneChip
Instrument System (http: //www.affymetrix .com/support/technical/manual/
expression_manual.affx). Briefly, spike controls were added to 10 pg fragmented
cDNA before overnight hybridisation. Arrays were then washed and stained with
streptavidin-phycoerythrin, before being scanned on an Affymetrix GeneChip
scanner. A complete description of these procedures is available at
http://bioinf.picr.man.ac.uk/mbcf/downloads/GeneChip_Hyb_Wash_Scan_Protocol_
v_2_web.pdf. Quality and amount of starting RNA was re-confirmed using an
Agilent Bioanalyser. After scanning, array images were assessed by eye to confirm
scanner alignment and the absence of significant bubbles or scratches on the chip
surface. For further discussion on the principles ofmicroarray see Chapter 7.
3.10 Microarray data analysis
Data were analysed by Richard Mitter, CRUK Bioinformatics and Biostatistics
Group, London using Bioconductor 1.8 (117) running on R 2.3.0 (118). Expression
measures were calculated using the 'Affy' package's Robust Multichip Average
(RMA) default method (119). Differential gene expression was assessed between X
and L cell lines for early (p4) and late (p8) passage cells using an empirical Bayes't-
test as implemented in the 'limma' package (120) (121) (122). Subsequent p-values
were subjected to multiple testing correction using Benjamini and Hochberg's
method for controlling the false discovery rate (123). Probe sets were called
differentially expressed if their adjusted p-values were below a cut-off of 0.05.
'simpleAffy' (124) and 'hgul33plus2' (125) packages were used to link Affymetrix




Cells were seeded in 96-well plates at increasing densities (500 to 5000 cells per
well) in 200ql media. Every 24 hours the number of cells present were estimated by
SRB assay (see below for more detail) (126). The growth curve for each cell line was
then constructed. The optimal cell density is defined as the cell density that gives an
optical density of >1.5 when the cells are allowed to grow for three doubling times.
A graph is drawn of log cell number against time, the equation parameters for
exponential growth are y=No.ekt. The doubling time is calculated according to the
equation t =ln2/k. The plating efficiency is the ratio between the number of cells
present after 24 hours when the media has been aspirated compared to no removal of
media.
3.12 Cell Characteristics
The floating cell fraction was determined by counting (Becker Coulter Counter) an
aliquot of the media from the tissue culture flask after the cells had been growing for
7 days. The adherent cells were then trypsinised and an aliquot counted. The floating
cell fraction was expressed as a percentage of the total adherent and floating cells
and the experiment repeated three times.
For morphological examination the media was changed immediately prior to
examination and cells visualised under a phase contrast microscope. Spot Insight
FireWire camera and software version 4.1 were used.
3.13 Annexin V-PI assay by flow cytometry
Apoptotic cells were detected by flow cytometric analysis using TACS Annexin V-
FITC kit (TA4638/TA5532 R&D systems, Abington, UK) according to
manufacturer's instructions. Exponentially growing cells, both floating and adherent
fractions, were collected using Cell Dissociation Solution to avoid membrane
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disruption and a single cell suspension formed, lxl06 cells were washed once with
cold PBS and resuspended in lOOpl reagent, incubated in the dark for 15 minutes at
room temperature. 400p.1 of IX binding buffer was added and cells analysed by flow
cytometry on the FACSCalibur (Becton Dickinson, San Jose, CA, USA) as described
in (127). FITC and PI emissions were detected in the FL-1 (Ex=488 nm, Em=530
nm, band width 30 nm) and FL-2 (Ex=488 nm, Em=575 nm, band width 42 nm)
channels, respectively. Cells were first analysed for the forward scatter vs. side
scatter distributions. Cell debris characterised by low FSC/SSC were excluded from
the analysis. The viable cells were then analysed on the FL-1 vs. FL-2 plot. HCT116
cells stained with PI or annexin V only were used to set up the compensation value
between the two channels. HCT116 cells (low PI and AV) stained with both PI and
AV were processed to define the 4 quadrants of interest: PI-/AV-, PI+/AV-,
PI-/AV+. The samples (10,000 cells) were then analysed using the same settings to
measure the distribution of the cells in the different quadrants: impermeable to both
PI and AV (PI-/AV-), permeable to PI but not AV (PI+/AV-), permeable to AV but
not PI (PI-/AV+), and permeable to both PI and AV (PI+/AV+). Data analysis was
performed with Cell Quest software.
3.14 DR5 expression by flow cytometry
For these studies Cell Dissociation Solution was used to remove cells from the tissue
culture flask to avoid potential disruption of the cell surface receptors with trypsin. A
DR5 primary antibody conjugated to phycoerythrin (Abeam ab 18365, Cambridge,
UK) was optimised to assess the cell surface receptor expression. Jurkat cells were
included as a control. 1 x 106 cells were washed with PBS, incubated for 30 minutes
in the dark with antibody or 3% BSA control. Cells were then washed three times
with PBS and analysed by flow cytometry. The procedure was optimised as
described for AV-PI staining.
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3.15 In vitro cytotoxicity using the SRB assay
Cytotoxicity in vitro was assessed using a cell death assay based on detection of cells
by sulforhodamine B (SRB), a stain specific for proteins (126). Each cell line was
plated in 96-well plates according to the optimal seeding density (2000 - 5000 cells
per well) in 150pl media. To achieve log phase cell growth at the start of treatment
cells were allowed to attach and grow for 72 hours. Drugs were added over a
concentration range in 50pl media and incubated for 72 hours (for rhTRAIL
experiments shorter time points were necessary). The cells were fixed with
trichloroacetic acid (TCA), 10% final concentration, and the plates were incubated
for 1 h at 4°C. Wells were washed gently under running water and allowed to air dry.
SRB 50pi was then added to each well and the plates incubated 30 min at room
temperature. The excess SRB was then removed with 4 washes of 1% acetic acid and
the plates allowed to completely air dry. Tris-HCl, pH 10.5, 150pl was then added to
each well and the plates incubated for 1 hour at room temperature on a mixing
platform. Absorbance was read at 540nm on a Biohit BP800 microplate reader (Bio-
Hit, Helsinki, Finland). For radiotherapy studies, cells were seeded in 96-well plates
in triplicate at the optimal seeding density and left to attach for 24 hours. Gamma
radiation was applied over a dose range 0 - 16 Gy adhering to local safety
guidelines. Cells were then incubated at 37°C for 120 hours prior to SRB assay.
Three independent experiments were performed.
3.16 In vitro cytotoxicity using the MTT assay
Cells were plated in triplicate according to the optimal seeding density as described
above and allowed to adhere for 24 hours prior to cytotoxic treatment. Cells were
incubated with 0.2mg/ml MTT for 3 hours in the dark at 37°C (128). Medium was
then removed and formazan crystals solubilised in 200pl DMSO. The optical density
was measured at 570nm using a Biohit BP800 microplate reader. Experiments were
performed three times and the results expressed as a percentage of viable cells
compared to untreated controls using GraphPad Prism 3 software.
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3.17 Caspase 3/7 activity
Caspase 3/7 activity was estimated by cleavage of fluorescence peptide substrate in
the ApoOne caspase 3/7 assay (Promega) according to manufacturer's instructions.
Briefly, an equal volume of homogeneous caspase 3/7 reagent (Z-DEVD-Rhodamine
110 and lysis buffer ratio 1:100) was incubated with cells in a white-walled 96 well
plate at room temperature on a plate mixer for 21 hours. The fluorescence was
detected by excitation 485nm and emission at 538nm on a Fluoroskan Ascent FL
platereader (Thermo Labsystems, Waltham, MA, USA) using Ascent software
version 2.4.1. Experiments were performed three times and results expressed as the
difference between treated and untreated cells or relative to the parental cell line.
3.18 In vivo xenograft establishment
Animal experiments were carried out under a project licence issued by the UK Home
Office and UKCCCR guidelines (129) were followed rigorously. Studies were
performed in C57/B16 Nu/Nu mice 6-weeks old bearing bilateral xenografts, five
animals per group (10 xenografts). 10 million cells per flank were implanted
subcutaneously in a final volume of 200 pi RPMI and two dimensional volume
measurements taken three times per week with electronic callipers. Tumour volumes
were calculated using the formula V = [L x (W2/2)]. Xenografts were collected on
day 26, dissected to remove surrounding mouse tissue and blood vessels, and snap
frozen in liquid nitrogen. For therapeutic studies, treatment started 7 days after
• • • ^
implantation when tumour size reached 50-100 mm .
3.19 Statistical analysis
Growth inhibition curves were plotted as percentage of control cells and IC50 values
were determined by GraphPad Prism 3 Software (San Diego, CA, USA). Other data
are expressed as mean values ± standard deviation and an unpaired two-tailed t-test
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4.1 Introduction
A panel of five colorectal cell lines will be characterised and the results described in
this chapter. The cell lines were investigated for their MLH1 and p53 protein status
as these two features are known to be of clinical importance in colorectal cancer. The
response to chemotherapeutic agents may vary depending on the expression of p53
and MLH1; Magrini et al investigated the effects of these two proteins in response to
CPT11 treatment in isogenic derivatives of the HCT116 cell line and found that the
mechanism of cytotoxicity varied (47). CPT11 was found to induce long term G2/M
arrest in p53+ cells and short term growth arrest followed by apoptosis in p53- cells.
In addition lack of the MLH1 protein enhances apoptosis in CPT11 treated HCT116
cells. Meyers et al were able to demonstrate that MLH1 deficient cells were more
resistant to 5FU compared to mismatch proficient HCT116 cells (130). Therefore it
is important to characterise the colorectal lines as their response to clinically
important chemotherapeutic agents may differ.
It is also necessary to establish XIAP mRNA and protein levels in the panel of colon
cancer cell lines prior to further investigation in order to identify an appropriate
model for further study. Publicly available data on NCI/NIH Developmental
therapeutics website (http://dtp.nci.nih.gov/mtweb/search.jsp) was accessed to
directly compare the results of this study at the mRNA level. The levels of XIAP
across the NCI panel of cell lines has previously been described in the literature (82,
86) and, although this data cannot be directly compared, it provides confidence in the
methods used. The mRNA levels of three other members of the IAP family (CIAP1,
CIAP2 and Survivin) are also presented with comparison to NCI data in addition to
the negative regulator of XIAP, XAF1.
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XIAP protein levels were investigated in an isogenic system to assess whether
differences occur according to p53 or MLH1 status. The HCT116 cell line represents
the parental wild type, HCT116 p53- is a p53 null cell line, HCT116 Chr3 has had
Chromosome 3 replaced to provide a functional mismatch repair (MMR) system,
HCT116 Chr3/M2 is a derivative of the previous cell line which serves as a control
for the addition of an extra chromosome but with deficient MMR system.
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4.2 Results
4.2.1 XIAP mRNA Levels
Total RNA was extracted from a panel of cell lines using the method described in
Chapter 3. Figure 10 shows the comparison between results from this study and data
published from the NCI/NIH Developmental therapeutics program. The qRT-PCR
results correlate well with the NCI data for 4 out of 5 of the colorectal cancer cell
lines, the exception being Colo205. Up regulation of XIAP mRNA is seen in all 5
colon cancer cell lines in comparison to normal adult human liver by qRT-PCR; the
NCI data has no normal tissue comparison.
Figure 10: Left axis displays XIAP mRNA levels in lOng total RNA by RT-PCR for a panel of
colorectal cell lines, relative to human adult liver. Error bars show standard error of mean for
triplicate reactions in the Rotorgene run. Right axis shows data from the NCI database (no
normal tissue comparison).
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Figure 11 shows the variability of the NCI data for XIAP levels by RT-PCR relative
to HCT116. The cell line colo205 shows a large inter-experiment variability which
may explain the difference in XIAP levels for this cell line seen in Figure 10.
Experimental variabilityof NG data
colo205 KT29 SA620 HCT15 HCT116
Colorectal Cell Line Panel
Figure 11: Experimental variability of NCI data. XIAP levels by RT-PCR from nine
experiments from NCI for each of the five cell lines relative to HCT116
4.2.2 Characterisation of protein levels by Immunoblot
XIAP protein levels across the panel of colorectal cancer cell lines are shown in
Figure 12. All of the cell lines express XIAP; HCT15 has the lowest levels and
SW620 the highest. For SW620 a double band is seen; further optimisation of the
experimental conditions may be required for this cell line.






Figure 12: Western Immunoblot comparing protein levels of P53, MLH1 and XIAP across a
panel of colorectal cell lines.
The p53 and MLH1 status across the colorectal cell line panel is shown in Figure 12
with publicly available data shown in Table 4 for comparison. The FICT8 cell line
was included in this gel, but not in other studies and the data is shown to avoid
cutting the gel. HCT116 is the only MLH1 deficient cell line in the panel studied
which is consistent with NCI data (http://discover.nci.nih.gov/
cellminer/loadDownload.do). p53 levels correlate with mutation status when
compared to data from the Sanger institute (http://www.sanger.ac.uk/
genetics/CGP/cosmic/) with the exception ofHCT15 where p53 was mutated in their
data.
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Colo205 HT29 SW620 HCT15 HCT116
P53 mut mut mut mut WT
MLH1 + + + + -
Table 4: P53 (Cosmic, Sanger Institute), MLH1 (CellMiner, National Cancer Institute) status
for comparison with Figure 12.
4.2.3 XIAP in an isogenic HCT116 system
XIAP protein levels in HCT116 derivatives with variations in their p53 and MLH1
status are described in Figure 13. The results shown confirm the p53 and MLH1
status of these isogenic cell lines. The XIAP levels do not appear to vary across
derivatives of HCT116 indicating that alterations in p53 or MLH1 protein levels do
not affect the expression ofXIAP in a quantitative manner.
P53





HCT116 HCT116 HCT116 HCT116
P53- Chr3 Chr3/M2
Figure 13: p53, MLH1 and XIAP levels by Western Immunoblot in isogenic HCT116 colorectal
cell lines.
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4.2.4 mRNA expression of other lAPs and XAF1
The levels of other IAP family members cIAPl, cIAP2 and survivin (Figure 14) were
also quantified. These were found to be elevated by qRT-PCR in comparison to
normal human liver although the correlation of expression in cancer cell lines with
NCI data was inconsistent. This could be due to inter-experiment variability as
described with XIAP in Figure 11 above or differences in the stage of cell cycle as
the cells were not synchronised prior to RNA extraction.
XAF1
Figure 14: mRNA expression of IAP family members cIAPl, cIAP2 and survivin across the
panel of colorectal cancer cell lines with normal human liver by qRT-PCR compared to the data
from NCI. XAF1 mRNA expression across the panel of cell lines by qRT-PCR. Error bars show
standard error of the mean for triplicate reactions in the Rotorgene run.
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XAF1 levels are low in 3 out of 5 of the cancer cell lines compared with normal
human liver (Figure 14). Two of the cell lines (HT29 and Colo205) have much
higher levels (2 orders ofmagnitude) than those seen in normal tissue. No correlation
between XIAP and XAF1 levels was seen.
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4.3 Discussion
There is good correlation between XIAP qRT-PCR data generated in these studies
and the publicly available results with the exception of the Colo205 cell line. The
Colo205 cell line shows the most inter-experimental variability in the NCI data and it
was therefore excluded as a candidate for further study. These data validate the
primers which were designed (see methods) and the accuracy of qRT-PCR as a
technique in the quantification of XIAP mRNA levels. Levels ofXIAP, CIAP1 and
CIAP2 have been described in the literature (82, 86) although it is difficult to
compare these results as different experimental techniques and analysis were used.
Of the 5 cell lines examined, HCT116 has the least (10 times) up regulation of XIAP
compared to adult human liver. Takeuchi et al describe similar levels of XIAP up
regulation (one order ofmagnitude) when comparing human colon adenomas to liver
metastases by qRT-PCR (92) hence this model is relevant in the clinical setting.
The HCT116 cell line is deficient in MLH1 which is consistent with previous reports
(47, 130). The results shown here describe no variation in XIAP depending on the
MLH1 or p53 status. Krajewska et al (88) studied the protein expression in human
colorectal tissue of several apoptosis biomarkers. They found that microsatellite
unstable tumours revealed significant differences for p53, CIAP1 and CIAP2
immunostaining but no difference for XIAP, survivin, smac or BCL2 family
members. Therefore we may assume that the MLH1 protein expression of the cell
line does not affect XIAP expression. It is well documented that there are genetic
differences between tumours which are microsatellite stable and unstable in terms of
their p53 status. Cummins et al developed a XIAP knockout model by gene deletion
(131) using two colorectal cancer cell lines which differed in their p53 status and
found a consistent phenotype. This implies that XIAP expression is independent of
p53 status; our data confirm such findings.
There are no data available from the NCI for expression of the negative regulator of
XIAP, XAF1. However, Fong et al (82) describe low XAF1 expression in cancer cell
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lines of the NCI60 panel by RT-PCR with the exception of Colo205 where the levels
were higher than average, consistent with our study. They describe very low XAF1
levels in the HT29 cell line which is inconsistent with the data presented here; our
experiment may need to be repeated under different cell growth conditions.
Generally levels of XAF1 are lower in cancer cells when compared to normal cells,
leading to its identification as a possible tumour suppressor gene. To date no specific
mutations of XAF1 have been identified although the gene is located within an area
of loss of heterozygosity at 17p 13 (82). More recently hypermethylation of the
promoter region of the XAF1 gene has been described resulting in repression of
transcription (132) which would explain the low levels ofXAF1 in tumour cells.
The HCT116 cell line is mismatch repair deficient (MLH1-) but has a normal
functioning p53. It expresses XIAP at levels similar to the other members of the
colon cell line panel and is up regulated compared to normal tissue. HCT116 is a
well characterised cell line which is easy to grow in vitro, readily modifiable and all
the isogenic lines grow well as xenografts, making a good candidate for further
study.
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In Vitro Studies with AEG35156 (XIAP Antisense)
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5.1 Introduction
In vitro studies with AEG35156 (XIAP Antisense) in the HCT116 colorectal cancer
cell line will be described in this chapter. Transient transfection of antisense is a well
established in vitro method of target down regulation. Delivery of antisense requires
the use of transfection reagents such as Lipofectamine™ 2000 (LFA™2000) which
intermittently disrupts the cell membrane allowing the oligonucleotide to enter the
cell. The use of any transfection reagent may bias experimental results and therefore
appropriate controls are necessary. In the following experiments there are 3 controls
(Opti-MEM®, Phosphate Buffered Saline (PBS) and AEG35187 missense (MS)) and
one experimental (AEG35156 XIAP antisense (AS)). The "Opti-MEM®" group
represents the addition of serum free media with no LFA™2000 thus when compared
to the "PBS" group (phosphate buffered saline plus LFA™2000) assesses the effect
of the transfection reagent. When "MS" is compared to "PBS" the effect of the
backbone structure of the drug may be delineated. The specific effect ofXIAP down
regulation is therefore only seen when comparing "AS" to "MS". In most
experiments the targeted oligonucleotide does not cause toxicity to the cell but here it
has the potential to do so as it is mounted on a phosphorothioate backbone hence the
need for a backbone (missense) control.
For clinical development of the compound the backbone is essential to prevent
breakdown of the targeted structure by enzymes after intravenous (IV) injection.
Therefore the effect of this structure should also be assessed in vitro. The aim was to
assess the cytotoxicity of this oligonucleotide with a view to combination studies
with recognised cytotoxic agents and further in vivo studies. First the
pharmacodynamic effect of the new compound was confirmed by quantification of
the XIAP mRNA levels in a cell; this required optimisation of the transient
transfection method. Second the dose range of the new compound was identified in
order to balance the drug toxicity with the pharmacodynamic effect.
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5.2 Method Optimisation
Two methods for transfection of antisense oligonucleotides were evaluated:
5.2.1 One day transfection
The day prior to transfection HCT116 cells were plated in 6-well tissue culture plates
in triplicate at a seeding density of 1 x 106 cells per well (no antibiotics were added
to media) and incubated overnight. Antisense (AS), missense (MS) or phosphate
buffered saline (PBS) were added to the cells with Lipofectamine™ 2000
(LFA™2000) according to manufacturer's recommendations. A control using Opti-
MEM® only without LFA™2000 was also included to assess the effect of the
transfection reagent. Oligonucletide dilutions and complexes were made in Opti-
MEM (Invitrogen) reduced serum medium at a final concentration of 400nM or
1200nM. After 6 hours the medium was replaced and the cells were incubated for 24
hours prior to RNA extraction and XIAP level analysis by qRT-PCR. This method
using AEG35156 has previously been described (133) in the non-small cell lung
cancer cell line H460. For cytotoxicity assays (SRB, MTT and caspase 3/7 activity)
the above protocol differed only in that 96 well tissue culture plates were used; the
reagents were scaled according to the manufacturers recommendations keeping the
drug concentrations accurate.
5.2.2 Two day transfection
The protocol above was followed and the cells transfected on the first day as above.
After 6 hours incubation the medium containing complexes was removed and
replaced for overnight incubation. The next day a further 6 hour transfection was
performed. XIAP mRNA levels were quantified by qRT-PCR and cytotoxicity
studies performed as described in Chapter 3. Increasing OGN concentrations were
investigated and at the lOOnM and 400nM doses, RNA was extracted to assess the
extent of XIAP knockdown. The 400nM dose allows comparison with the one-day
transfection protocol described above and the 1 OOnM dose was chosen from the IC50
value of the SRB cytotoxicity assay (see Figure 20 below).
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5.3 Results
5.3.1 One day transfection protocol
5.3.1.1 XIAP down regulation
The results of the one day transfection protocol at 400nM and 1200M are shown in
Figure 15. Two sets of controls were investigated - PBS transfected and Opti-MEM®
media only. No difference in the XIAP levels between the two controls was seen at
either dose level (data not shown). Results are therefore shown relative to the PBS
control as this is the solvent used for the AS and MS drugs. At the dose of 400nM a
down regulation of 33 ± 8% (p<0.02, t-test) was seen in the AS treated cells relative
to the PBS control with no change seen in the MS. At a dose of 1200nM a down
regulation of 67 ± 9% (p<0.001, t-test) was seen with the AS. However the MS
caused a 35 ± 13% (p<0.02, t-test) decrease in XIAP levels at this concentration.
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Figure 15: XIAP mRNA levels by qRT-PCR relative to the PBS transfected control at two
concentrations (400nM and 1200nM) using the one day transfection protocol. Error bars
represent standard deviation from the mean for three separate RNA extractions.
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5.3.1.2 Cytotoxicity
To investigate whether this decrease in XIAP mRNA levels translated into
cytotoxicity MTT and SRB assays were performed (Figure 16 and Figure 17)). There
is no significant difference in either the ratio of cells fixed to the plate or the ratio of
viable cells at increasing drug concentrations. In both assays there is cell death
compared to the PBS transfected control in both the AS and MS treated groups. This
implies that it is the phosphorothioate backbone which is present in both the AS and
MS and not the down regulation of XIAP which is cytotoxic to the cells. In the MTT
assay (Figure 16) maximal cytotoxicity is seen at a dose of 600nM whereas in the
SRB assay (Figure 17) the maximum is seen at a dose of 400nM. This may
potentially be explained by differences in the floating cell fraction. In the MTT
method the active compound is added into the media of the tissue culture plate and
all respiring cells produce formazan crystals which are then quantified. With the SRB
assay the adherent cells are fixed onto the plate with trichloroacetic acid which
precipitates proteins which are then stained for quantification. At a dose of 600nM
there is a 20% difference in the ratio of cells (0.7 MTT and 0.5 SRB). Therefore it is
possible that during these experiments detached cells are respiring. It is important to
recognise that detached cells are not necessarily dead and in this case there is a
fraction of 20% which are viable but not attached to the plate. If it is the toxicity of
the phosphorothioate backbone which is causing the cells to detach, the floating cell
fraction therefore needs to be assessed for XIAP status. The design of further
experiments was therefore altered to avoid removal of detached cells.
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Figure 16: MTT cell viability assay at varying oligonucleotide concentrations using the one day
transfection protocol. Error bars represent standard deviation from the mean for triplicate
wells in the experiment.
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Figure 17: SRB cytotoxicity assay at varying oligonucleotide concentrations using the one day
transfection protocol. Error bars represent standard deviation from the mean for triplicate
wells in the experiment.
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Cytotoxicity of the lower oligo doses (0 to 400nM) by SRB assay is shown in Figure
18. This was investigated as there was a suggestion that at lower doses (as seen in
Figure 17 above) there may be a separation of the AS and MS lines. Two methods
were employed - removing the media after 6 hours transfection then replacing with
standard cell culture media (RPMI + 5% FCS) for 18 hours (dotted lines) or leaving
the transfection mix in situ for 24 hours (solid lines). In both cases the media was
removed after 24 hours in order to perform the SRB assay. When transfection was
carried out for 24 hours, a dose-dependent cytotoxicity was observed, a maximal
difference between MS and AS being obtained at the 200nM dose (survival fraction
= 73 ± 4% for AS, p<0.0002 by t-test and 85 ± 3% for MS, p<0.02 by t-test). A
shorter transfection (6 hours) led to a similar pattern of cytotoxicity: A maximal
differential cytotoxicity between MS and AS was observed for a concentration of
200nM (survival fraction = 67 ± 4% for AS, p<0.002 by t-test and 81 ± 3% for MS,
p<0.05 by t-test). Removal of the complexes at 6 hours compared to a 24 hour
transfection does make a small difference in all 3 groups. The fact that the difference
is most prominent in the PBS transfected group implies that long incubation of the
transfection mix causes up to 10% increase in cytotoxicity to the cells and is not drug
related. This method was therefore abandoned in favour of replacing the media after
6 hours.
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Figure 18: SRB cytotoxicity assay at varying oligonucleotide concentrations using the one day
transfection protocol. Error bars represent standard deviation from the mean for triplicate
wells in the experiment. Solid Lines represent transfection mix left on for 24 hours. Dotted Lines
represent transfection mix removed after 6 hours and replaced with media.
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5.3.2 Two Day Transfection Protocol
Using a single 6-hour transfection, a non-specific effect of the backbone of the
oligonucleotide was observed at high doses (1200nM). At a lower oligo dose
(400nM) this non-specific effect was not observed, however, the down regulation of
XIAP was limited. Therefore, a second method was developed using a two day
transfection protocol (two x 6 hours) after literature review (41).
5.3.2.1 XIAP down regulation
The pharmacodynamic effect of AEG35156 was assessed by qRT-PCR using the two
day transfection protocol described above. At the lOOnM concentration, relative to
the PBS transfected control, a 72 ± 3% (p<0.004, t-test) down regulation of XIAP
was seen for the antisense group and 44 ± 8% (p<0.005, t-test) for the missense
group at the mRNA level (Figure 19). At the 400nM concentration an 81 ± 4%
(p<0.04, t-test) down regulation of XIAP was seen for the antisense group and 69 ±
5% (p<0.09, t-test) for the missense group. These results imply that there is a
significant non-specific effect of the missense for both doses using this transfection
protocol. This protocol does achieve a level ofXIAP down regulation consistent with
the stable knockdown clones described in Chapter 7.
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In Vitro Transfection (2x 6 hours) of AEG into
HCT116 cells
AS MS PBS
Figure 19: XIAP mRNA levels by qRT-PCR relative to the PBS transfected control at two doses
(lOOnM and 400nM) using the two day transfection protocol. Error bars represent standard
deviation from the mean for three separate RNA extractions.
5.3.2.2 Cytotoxicity
In order to ascertain whether this level of knockdown conferred cytotoxicity to
colorectal cancer cells experiments were performed between 0 to 400nM of the AEG
compounds (Figure 20). At a dose of lOOnM 38 ± 7% of cells were alive in the AS
group and 53 ± 7% in the MS group. At a dose of 400nM 15 ± 2% of cells were alive
in the AS group and 24 ± 4% in the MS group. Therefore the transient transfection of
AEG 35156 (XIAP antisense) does cause cell death in a dose dependent manner
using this protocol however the missense control (AEG 35187) also results in a
similar effect. This highlights the need for adequate controls when performing these
experiments.
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Figure 20: SRB cytotoxicity assay at varying concentrations using the two day transfection
protocol. Error bars represent standard deviation from the mean for triplicate wells in the
experiment. The IC50 dose of lOOnM was chosen in order to maximise the effect between the
MS and AS whilst still achieving XIAP down regulation.
5.3.2.3 Growth Curves
The growth pattern following XIAP down regulation is described in Figure 21 using
a lOOnM two day transfection. As described previously (Figure 19) 72% and 44%
knock down were identified in the AS and MS groups, respectively. The adherent
and floating cell fractions were harvested from 6 well plates and reseeded in 96 well
trays prior to performing the SRB assay at daily time points. The AS and MS treated
groups were unable to reattach to a tissue culture plate in contrast to the PBS
transfected cells.
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Figure 21: Growth curve by SRB assay for an identical number of cells re-seeded in a 96 well
plate following the two day transfection protocol (concentration lOOnM). Error bars represent
standard deviation from the mean for triplicate wells in the experiment.
5.3.3 Comparison of two protocols
The results previously described in Figure 15 and Figure 19 are summarised in
Figure 22 where the two transfection protocols are compared at the same dose of
400nM. The two day protocol achieves a higher XIAP knockdown (81% compared
to 33%) with antisense but there is a substantial decrease in XIAP (69%) in the
missense group with the two day protocol. The remainder of the experiments were
therefore conducted using the one day protocol at the 400nM concentration in order
to minimise the non-specific effect of the missense oligonucleotide. These conditions
have shown cell cytotoxicity by SRB assay.
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Figure 22: Comparison of XIAP mRNA levels by qRT-PCR relative to the PBS transfected
control after one and two day transfection protocols at 400nM concentration. Error bars
represent standard deviation from the mean for three separate RNA extractions.
5.3.4 TRAIL Treatment
The next series of experiments focussed on caspase 3 activity as a marker of
activation of the apoptotic pathway. TRAIL was added to stimulate the pathway and
to assess whether XIAP knockdown sensitised to this known cytotoxic agent. The
caspase 3 assay relies on cells which are fixed to the plate and, as shown above
(Figure 17), both the AS and MS treated groups detach from the cell surface
therefore an SRB assay was performed simultaneously and the results expressed per
unit OD value.
Comparison of the caspase activity in Figure 23 in the transfection only group (blue
bars) shows a doubling of activity between the control (PBS 460 +/- 60) and both the
AS and MS treated cells (AS 980 +/- 120, MS 900 +/- 70). It should be noted that
there is 33% down regulation of XIAP in the antisense group only using this
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protocol. These data add weight to the argument that it is non-specific backbone
effect of the drug which is causing death, and here we confirm that the mechanism of
that cell death is by apoptosis.
Figure 23 also shows the caspase 3/7 activity per cell after TRAIL treatment to
directly stimulate the extrinsic apoptotic pathway following transfection of AEG
compounds (yellow bars). Although the antisense + TRAIL had a 3 fold increase in
caspase activity when compared to PBS (1620 ± 70 for PBS + TRAIL and 5270 ±
740 for AS + TRAIL, respectively), the missense + TRAIL showed a 2.5 fold
increase (4120 ± 470), suggesting that the presence of an oligonucleotide rather than
down regulation of XIAP was responsible for this effect. The effect of TRAIL alone
(red bars) was similar across the 3 groups (PBS 1670 ± 70, AS 1660 ± 50, MS 1590
± 100) which confirmed robust experimental technique.
In vitro Transfection of AEG (1x 400nM) for 24
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Figure 23: SRB and Caspase 3/7 assays performed in tandem to allow expression of caspase 3/7
activity per cell present. One day transfection protocol using 400nM concentration, the cells
were then treated with 5ng/ml TRAIL and assays performed. Error bars represent standard
deviation from the mean for triplicate wells in the experiment.
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5.4 Discussion
Hu et al (133) describe a method of a single 6 hour transfection with assessment of
pharmacodynamic effect at 24 hours at the protein level, this gives a maximum
reduction in XIAP levels of 62% at a dose of 1200nM. This study focused on a
library of first generation chemistry antisense oligonucleotides and subsequently
second generation technology has led to the design of a phosphorothioate backbone
(107). The second generation chemistry of the AEG compounds has improved in vivo
pharmacokinetics and therefore the two cannot be directly compared and may
explain the differences in results. These experiments were performed in a different
cancer cell line and therefore the technique is likely to require some modification for
use in a colorectal cancer model but it does provide a valuable starting point. The
results presented here assess pharmacodynamic effect at the mRNA level but this is
likely to be greater than that achieved at the protein level and therefore we have not
been able to achieve an adequate degree of down regulation in the antisense group
without significant non specific effects seen with the missense group.
McManus et al (41) describe a two day transfection technique in pancreatic cancer
cells using the same second generation antisense AEG35156 as in the experiments
described here. A 72% down regulation is seen in our studies at the mRNA level in
the colorectal cell line compared to a 70% reduction seen by McManus et al at the
protein level. The correlation between RNA and protein is similar to that seen in the
stable shRNA expressing knockdown clones generated in Chapter 7 (87% and 67%
for the X23 cell line). The concentration of 1 OOnM of oligonucleotide used here was
identical to the studies by McManus although reductions of XIAP protein were not
seen in the missense group. Again, this was a different cell line but the non-specific
effect was seen at the RNA level.
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McManus et al were also able to identify sensitisation to TRAIL after down
regulation of XIAP. From their data the approximate TRAIL doses required for 50%
survival of Panc-1 cells were O.lng/ml for AEG35156 and lOng/ml for AEG35187
transfected cells. This data was not replicated in the colorectal HCT116 cell line,
where only 2-fold sensitisation was seen, due to non-specific sensitisation with the
MS.
AEG35156 In Vitro 78
Chapter 5
5.5 Conclusion
In conclusion a transient transfection method was developed which achieved 81%
down regulation of XIAP mRNA using the AEG35156 compound. However, if this
method was used, down regulation of XIAP mRNA was also seen with the missense
AEG35187 compound. In order to achieve specific down regulation of XIAP only
with the antisense (and not missense) a one day transfection at 400nM should be
performed however the knockdown seen in this case is only 33%.
Cytotoxicity experiments show no significant therapeutic benefit of antisense over
missense; both show a maximal cytotoxic effect of approximately 50% above doses
of 400nM (one day protocol) and approximately 80% at doses above 200nM (two
day protocol). Investigation of stimulation of the extrinsic apoptotic pathway with
TRAIL following 33% XIAP down regulation does not confer a significant increase
in apoptosis when compared to the missense control.
Combination studies with other recognised cytotoxics are unlikely to be effective
with this level of selective down regulation of XIAP mRNA. Therefore a stable
siRNA model of XIAP knockdown was developed and will be further described in
Chapter 7.
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6.1 Introduction
The in vitro antisense studies described in Chapter 5 failed to show a specific effect
of AEG35156 when compared to its missense control (AEG35187). However
LaCasse el al have shown a 60% reduction in tumour volume in vivo for LS174T
human colon xenografts treated with XIAP AS 25mg/kg/day when compared to a
saline control. The antisense was also shown to be effective as a single agent in vivo
in PC-3 prostate xenografts and in combination with docetaxel in H460 lung
xenografts therefore the compound has been taken into Phase 1 clinical trial (40). In
the same publication (40) dose dependent XIAP down regulation could not be
demonstrated at the mRNA level when H460 and PC-3 cells were treated with XIAP
AS in vitro compared to the nonsense control AEG35185; the data were not shown
for LS174T in vitro.
Therefore, inconsistency exists between in vitro and in vivo data and a set of
experiments were performed in an in vivo mouse model as an example of a
physiological system. In this chapter two studies are described; first the anti-tumour
effect and toxicity of the AEG compounds. Secondly, following demonstration of an
anti-tumour effect a pharmacokinetic (PK) and pharmacodynamic (PD) study was
/
undertaken to assess the extent of knockdown in the model system.
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6.2 Methods
6.2.1 Anti- tumour effect
The study was performed by staff in the CRUK Biomedical Research Facility and
supervised by Dr S Guichard. Her expertise is acknowledged and the results
presented here with her permission. Animals were randomised into 3 groups: control,
AEG35156 and AEG35187. Ten animals were used in the control group, 5 in each of
the treated groups. Animals were treated by intraperitoneal injection of AEG35156
(XIAP AS) or AEG35187 (XIAP MS) at a dose of 25 mg/kg/d dx5 for 3 consecutive
weeks, formulated in PBS. Control animals received vehicle (PBS) only. Tumour
measurements and body weight were determined 3 times a week from start of
treatment. Toxicity was assessed by body weight loss (weight measured 3 times per
week) from the start of treatment to the recovery of the initial body weight. Efficacy
was determined using the time to reach 5 times the initial tumour volume (Td5Vo).
Statistical analysis was by comparison of Kaplan-Meier curves using a Log-Rank
test.
6.2.2 Pharmacodynamic effect
This study was designed to incorporate pharmacokinetic and pharmacodynamic
analyses. An HPLC based assay was being developed for another project in the
PDDG relating to Bcl-xl AS and it was intended to adapt this assay for use with
XIAP antisense. Unfortunately, difficulties related to the extraction of AS from
biological matrices could not be overcome and therefore PD data alone will be
presented here. The aim was to quantify the uptake of XIAP AS, the differential
extent of XIAP knockdown and define the time course of both tissue retention and
knockdown in mouse liver and human HCT116 xenograft tissue. The antisense
oligonucleotide sequence remains under copyright and therefore has not been
disclosed, but it should be noted that there is a 3 base pair mismatch between the
mRNA sequence ofmouse and human XIAP in the target region.
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Data are presented for both the human tumour HCT116 xenografts and mouse liver
XIAP mRNA levels. 24 hours after the completion of one, two or three weeks of
treatment (days 6, 13 and 20 respectively) tissue was collected to establish whether
the effect of XIAP antisense is cumulative. RNA was also extracted at 24, 72 and
168 hours (days 13, 15 and 19 respectively) after two weeks of treatment to assess
the time point at which maximal XIAP down regulation occurs in order to aid
schedule design of any potential combination studies with cytotoxic agents. The
experiment was originally designed to extract the RNA at time points after a total of
3 weeks treatment but the xenografts were growing faster than anticipated and
therefore the design was altered. This is discussed further below and the study plan is
summarised in Figure 24.
The technique ofRNA collection from in vivo samples was standardised to minimise
the degradation of the RNA prior to qRTPCR analysis. From each animal the right
flank tumour was trimmed to minimise any contaminating mouse tissue, snap frozen
and stored at -70°C. The liver samples were immediately placed in RNAlater®
solution to prevent degradation then stored at -70°C. RNA extraction was performed
with TRI reagent® and all samples were DNase treated as described in Chapter 3.
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Figure 24: Schematic representation of the PK/PD study plan showing sample collection points
and treatment times.
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6.3 Results
6.3.1 Tumour growth before start of treatment
The tumour volumes for each group from 5 days before the start of treatment until
the day of randomisation are presented in Figure 25. The average tumour volumes















Figure 25: Tumour volumes from day -5 to day 0 before treatment. Tumour volumes are
presented to show that on day 0 the randomisation did not generate any bias between groups.
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The histogram of the tumour volumes for the HCT116 xenograft on day 0 is shown
in Figure 26 which conforms to a gaussian distribution. Moreover, the tumour
volumes all fell within the range specified for start of treatment: 50-150 mm3. These
parameters are important to assess prior to any in vivo study to prevent the
introduction of bias when measuring xenograft growth response to drug treatments; if




Figure 26: Histogram of tumour volumes on day 0 (randomisation) in the efficacy study.
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6.3.2 Toxicity of AEG35156 and AEG35187
Toxicity was monitored by daily weighing of the animals and the mean percentage
weight loss for the different groups of animals is presented in Figure 27. AEG35156
induced a significant weight loss at the dose of 25 mg/kg/d. This appears to be
specific since no weight loss was observed in the animals treated with AEG35187 or





Figure 27: Body weight loss monitored from the first day of treatment to day 16 (treatment on
day 0-4, 7-11, and 14-18). Data presented are average of 10 (control), and 5 animals (AEG35156
and AEG35187). As animals were culled due to tumour growth, the number of animals per
group decreased to 3,3, and 3 for control, AEG35156 and AEG35187, respectively.
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When individual data were examined for each tumour, inter-individual variability
was observed but the weight loss, when occurring, increased during treatment. Two
cut-offs of 5 and 10% of body weight loss were used: Animals crossing these cut¬
offs at any one time during the experiment were considered positive. Table 5
summarises the data.
> 5% BWL >10% BWL
Control (PBS) AEG35156 Control (PBS) AEG35156
HCT116 3/10 5/5 1/10 3/5
Table 5: Body weight loss of animals bearing HCT116 xenografts when treated with AEG35156.
6.3.3 AEG35156 anti tumour effect
Tumour growth was recorded from start of treatment until tumours reached 5 times
the initial volume (5Vo). Tumours were analysed individually despite being bilateral
tumours in most cases. Results are presented as average tumour growth (Figure 28)
or expressed as number of days to reach 5Vo, presented in Figure 29 as Kaplan-Meier
curves. Table 6 below summarises the average growth (Vt/Vo) for each xenograft.
Xenograft Day Group Mean Growth on Day 11 SD P value by t-test
HCT116 11 Control (PBS) 4.8 1.4
AEG35156 3.2 0.8 0.03
AEG35187 4.6 0.6 0.8
Table 6: Mean growth of HCT116 xenografts following treatment with AEG compounds.



















Figure 28: Growth of HCT116 xenografts after treatment with vehicle only, AEG35156 25mg/kg
(dx5) x3 or AEG35187. Results presented are mean ± standard error of the mean.
Statistical analysis showed that AEG35156 induced a significant growth delay at day
11 in HCT116 xenografts as compared to control animals or animals treated with
AEG35187 (p=0.03, t-test). The data were confirmed by Kaplan-Meier analysis
(Figure 29) and clearly show a delay in tumour growth for EICT116 xenografts
following treatment with AEG35156 (p=0.02, log rank test).
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Figure 29: Antitumour effect of AEG35156 compared to control vehicle or missense






The treatment times and sample collection points for the pharmacodynamic study are
shown schematically in Figure 24. Using the technique described above, good quality
RNA was obtained as confirmed by Agilent Bioanalyser 2100 and shown in Figure
30.
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Figure 30: RNA extracted from mouse liver (PK/PD study) Agilent bioanalyser gel showing
good quality RNA.
Although the primary aim of this study was to assess pharmacodynamic effect, the
growth of the tumours was also recorded in an effort to confirm the results of the
efficacy study described above. The tumour volumes prior to treatment in this study
are shown in Figure 31 confirming no significant bias at randomisation of the groups
of animals. However when the mean volume of tumours in the pharmacodynamic
and efficacy studies were compared (Figure 25 and Figure 31), in the PD study the
volumes were lower (0.044 - 0.051 compared to 0.078 - 0.081 cm3).
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Figure 31: Tumour volume prior to treatment in PK/PD study. Error bars show standard
deviation from the mean.
The mean growth of the HCT116 xenografts may be seen in Figure 32; there was no
significant difference between the three groups. Differences in xenograft growth
between the two studies may be noted (Figure 28 and Figure 32). For example, at day
9 in the control group, the Vt/Vo was 3.7 in the efficacy study compared to 7.2 in the
pharmacodynamic study. Therefore AEG35156 appears to be effective in the study
with larger starting volumes and slower xenograft growth; further studies are
necessary to confirm these data. In the efficacy study the control group was treated
with phosphate buffered saline (PBS) whereas in the PK/PD study the control group
was treated with saline as these were the respective vehicles used for the AEG
compound dilution.







Figure 32: Growth of HCT116 xenografts in PK/PD study. Results show mean ± standard error
of the mean.
HCT116 xenografts did not show significant XIAP mRNA knockdown at any time
point at the dose 25mg/kg/dx5 in this model (Figure 33 and Figure 34). Also in this
study AEG35156 did not slow tumour growth compared to the PBS and missense
control groups. Establishing the drug levels in the tumour may have identified the
cause for this, but as stated above, an assay was not available.
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1
DAY 6 DAY 13 DAY 20
24 hours after treatment
Figure 33: XIAP knockdown per ng of total RNA in xenograft. Error bars represent the
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After 2 weeks treatment
Figure 34: XIAP knockdown per ng of total RNA in xenograft. Error bars represent the
standard deviation of the mean for 3 animals in the group.
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The levels of XIAP in mouse liver 24 hours after the end of one, two or three weeks
of treatment are shown in Figure 35. The percentage decrease in XIAP mRNA levels
in the AS group compared to the MS group are Day 6 21%, Day 13 25% and Day 20
42%. At the day 20 time point (24hours after 3 weeks of dx5 treatment) this result
reached statistical significance p=0.014 (t-test). These data suggest that the
pharmacodynamic effect of AEG35156 was therefore cumulative over a period of
three weeks. Previous experience suggests that AEG35156 has a long tissue half life
of approximately 14 days (personal communication, Aegera Therapeutics Inc) which
would be consistent with these results.
Figure 35: XIAF knockdown per ng of total RNA in mouse liver. Error bars represent the
standard deviation of the mean for 3 animals in the group.
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The levels of mouse liver XIAP mRNA 24, 72 and 168 hours after the end of two
weeks treatment are presented in Figure 36. The percentage decrease in XIAP levels
in the AS group compared to the MS group are Day 13 25%, Day 15 43% and Day
19 31%. At the day 15 time point (72 hours after 2 weeks of treatment) this result
reaches statistical significance p=0.05 (t-test). Therefore the maximal XIAP mRNA
down regulation occurred at 72 hours after treatment was completed.
2
1.8
DAY 13 DAY 15 DAY 19
After 2 weeks treatment
Figure 36: XIAP knockdown per ng of total RNA in mouse liver. Error bars represent the
standard deviation of the mean for 3 animals in the group.
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6.4 Discussion
The dose and schedule of the oligonucleotides (25mg/kg/day x5 for 3 weeks) by
intraperitoneal injection was taken from the in vivo studies carried out in similar
xenograft models; LaCasse et al described dose dependant efficacy of AEG35156
using this schedule in a LS174T colon cancer xenografts (40). Here we describe a
reduction in mean Vt/Vo from 4.6 ± 0.6 in the missense control group to 3.2 ± 0.8 in
the antisense group. The efficacy study therefore provided encouraging data for
XIAP antisense in an HCT116 colorectal cancer model and this schedule was
repeated for the pharmacodynamic study.
The above results could not be confirmed in the pharmacodynamic study and the
difference in starting volumes and growth rates between the two may explain some
of the results. In this model, it may be necessary to start with larger volume tumours
which have a slower growth rate in order for the AEG35156 to be effective.
Alternatively further investigation of the optimal solvent for the AEG compounds -
saline or PBS - may be helpful. The rationale for changing the protocol between the
two studies was provided by the pre-clinical characterisation study (40) and the
Phase 1 clinical trial (109) where saline was used as a vehicle for the
oligonucleotides. The difficulty in reproducibility implies that further optimisation of
this model is required. In retrospect during the initial efficacy study it would have
been beneficial to extract RNA or protein from the xenografts to indicate whether
XIAP down regulation had been achieved.
The toxicity of AEG35156 was assessed by monitoring the weight of the animals
throughout the efficacy study and significant weight loss was seen. In this study it
was found to be specific for AEG35156 whereas LaCasse et al describe weight loss
in animals treated with AEG35191, an oligonucleotide with a four base mismatch, in
addition to the antisense. The weight of the animals was seen to recover quickly on
cessation of treatment (40).
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In the pharmacodynamic study the choice of animal for cull at each time point was
not random as the xenografts were growing too rapidly to complete treatment. Three
weeks treatment was therefore given to the slowest growing xenografts. This will
introduce bias into the results which should be interpreted with caution.
The tumour pharmacodynamic results were disappointing in that XIAP mRNA
knock down was not demonstrated but perhaps not unexpected given the lack of
efficacy in this experiment and may be a reflection of the model.
The pharmacodynamic results from liver samples extracted showed XIAP down
regulation which was maximal 72 hours after the end of the infusion and is
cumulative after 3 weeks of treatment. The maximal knock down seen was 43% in
the liver which, although it is statistically significant, may not be clinically relevant
as down regulation of 80% was seen in the clinical trial (109). It must be taken into
account that AEG35156 is directed against human XIAP mRNA and there is a 3
base-pair mismatch with mouse XIAP (personal communication E. LaCasse).
Despite this XIAP down regulation was seen in the antisense group relative to the
missense group, suggesting particularly high concentrations in the liver. Supporting
this, the preclinical toxicology studies with AEG35156 describe dose dependent
accumulation of the oligonucleotides and its metabolites in the liver (113).
In the concurrent Phase 1 clinical trial (described in Chapter 2) the main toxicity
observed was liver function abnormality (transaminitis) which was cumulative and
reversible. Similar elevation of serum transaminases was the dose limiting toxicity in
a Phase 1 trial of mixed backbone oligonucleotide targeting the regulatory subunit of
protein kinase A (GEM231) (112). However, the exact nature of liver toxicity
remains undefined. It is thought to be a class effect of antisense oligonucleotides
which has been observed in other situations and was not related to the specific
knockdown of the target (134).
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Further investigation of the plasma liver function tests in our mouse studies would
have assessed whether transaminitis was seen in these animals. Correlation with
levels of XIAP knock down might then have provided further insight into the
mechanism of hepatic dysfunction seen in the clinical trial. The development of a
method of oligonucleotide quantitation in tissue by mass spectroscopy would also be
useful to correlate with XIAP levels in both the antisense and missense groups and
to assess the drug delivery to the xenograft.
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6.5 Conclusion
AEG35156 (XIAP antisense) initially appeared to have a significant effect on tumour
growth in HCT116 xenografts compared to the missense control AEG35187,
however a subsequent study was unable to confirm this. Weight loss was observed in
the antisense group which may correlate to toxicity in the animals.
Antisense directed against human XIAP caused target knock down in mouse liver
despite a 3 base pair mismatch. Mouse liver XIAP down regulation of 43% appeared
to be maximum 3 days after end of treatment and cumulative at 42%, 24 hours after 3
weeks of treatment.
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7 The Development of Stable XIAP Knock Down Cell Lines
using shRNA
7.1 Introduction
The development of clonal derivatives of the HCT116 cell line which express either
a short hairpin RNA against XIAP (X cell lines) or luciferase (L cell lines) is
described in this Chapter. This approach was taken for two reasons; first to assess the
longer term effects of stable down regulation of XIAP and second as an alternative
method to complement the "antisense" approach which is currently in Phase I
clinical trial. In addition, the difficulties of transient XIAP knockdown over a shorter
time period as discussed in Chapter 5 and seen with siRNA (135) can be avoided,
facilitating experiments with cytotoxic therapies over a period of 6 days. It is
possible that down regulation of XIAP over an extended time period causes
compensatory changes in a cell and therefore this was investigated further.
The genetic makeup of the clonal cell lines generated was compared at the RNA
level using a microarray genechip. The four X cell lines (XIAP knockdown) were
compared with the four L cell lines (luciferase expressing control) at 2 time points.
HCT116 cell line RNA was also included in the microarray study in order to assess
the changes between the parental cell line and luciferase expressing control (L lines)
and validate the L lines as an acceptable control. Therefore three groups were
studied; HCT116 (parental cell line), X (XIAP knockdown) and L (luciferase
control). The early passage cells (p4) were investigated to assess the acute changes
associated with XIAP down regulation and the late passage (p8) the sustained
changes. Four genes were selected for validation by qRT-PCR to assess whether
«
these data correlated with the changes seen on microarray, this would validate the
techniques and preclude the need for multiple RT-PCR experiments.
With any new cell line it is necessary to characterise the growth pattern, plating
characteristics and morphology to document any differences which need to be
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anticipated in the experimental design. Experiments to document the activity of the
apoptotic pathway are also relevant in this case to establish the effect of XIAP down
regulation alone before combination with other cytotoxic agents are considered.
7.2 Genechip Microarray
7.2.1 Principles of Microarray
The principles of microarray are visually described in Figure 37 which is taken from
the Affymetrix website (http://www.affymetrix.com). This technique is helpful in
comparing the differences in gene expression between 2 sample groups. The sample
RNA is labelled with a fluorescence emitting compound and gene expression can be
quantified according to the intensity of the coloured light signal when
complementary RNA (cRNA) binds to oligonucleotides on the genechip.
Synthetic DNA oligonucleotide probes of defined sequence interrogate the cRNA
derived from the target sample. A number of probes are designed from unique
regions at the 3' end of each transcript to give a set of probe pairs for each mRNA.
The precise location of each probe is a feature, and millions of features can be
contained on one array. By extracting and labelling nucleic acids from experimental
samples, and then hybridizing those prepared samples to the array, the amount of
label can be monitored at each feature.
Affymetrix GeneChipR Human Genome U133 Plus 2.0 Array analyses the
expression of over 47,000 transcripts and variants including 38,500 human genes.
There are 54,000 probe sets and 1,300,000 distinct oligonucleotides features.
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A)
RNA fragments with fluorescent tags from sample to be tested
Figure 37: Pictures from Affymetrix website. A) Fluorescent labelled RNA from sample binds to
complementary DNA fragment on GeneChip. B) Each feature (spot) is detected as red colour by
the scanner when the RNA binds to it.
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7.2.2 Probe Design
Oligonucleotide probes complementary to each corresponding sequence are
synthesised in situ on the array. Eleven pairs of oligonucleotide probes are used to
measure the level of transcription of each sequence represented on the GeneChip.
The high density of microarrays affords the ability to use multiple probes for each
expression measurement made. The use of multiple probes provides for high
sensitivity and reproducibility. The probe set - a combination of twenty two 25mer
probes - balances sensitivity and specificity, allowing for consistent discrimination
between signal and background noise and accurate data sets.
Each probe pair consists of an oligonucleotide that is a perfect match (PM) and one
that is a mismatch (MM) that has one base changed in the centre of the
oligonucleotide sequence. This probe pairing strategy serves as a control for non¬
specific hybridisation allowing the software to calculate a signal intensity for each
probe set and determine an absent, marginal or present result.
7.2.3 Quality Control
The scale factor is a value that the array intensity must be multiplied by to give the
target intensity of 100. The signal intensity values of every probe set on the array are
calculated, the highest and lowest 2% are removed and the remaining values are
averaged to give the average array intensity. The scaling factor is then calculated as
the value that adjusts the average array intensity to the set target intensity. This factor
is then applied at the individual feature level not the average signal intensity level.
The background intensity, derived from the intensity values of the lowest 2% of cells
on the chip, establishes an overall baseline intensity to be subtracted from all cells
before gene expression levels are calculated. Noise is derived from the standard
deviation of the background intensity measurement.
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Spike controls are added to the total RNA sample in varying amounts. BioB is added
at the lower limit of detection therefore, if there is too much noise present, low
abundance transcripts and the BioB will not be detected. Hybridisation efficiency is
only considered acceptable when the spike control genes are present in increasing
intensity BioB<BioC<BioD<CreX.
7.2.4 Experimental Design
The microarray experimental design can be summarised in Figure 38 below.
VECTOR XIAP
r 1 r i r i r 1 r i r i r v
HCT116 HCT116 L8 L15 L23 L24 X6 X10 X16 X23
Figure 38: Schematic representation of the design of microarray experiment
shXIAP HCT116 cells 104
Chapter 7
7.3 Results
7.3.1 Isolation of the cell lines and confirmation of XIAP status
Twenty four geneticin-resistant clonal cell lines were isolated after transfection with
shRNA expressing either XIAP (X clones) or luciferase (L clones). The levels of
XIAP mRNA were determined by quantitative RT-PCR (Figure 39) and identified
four X clones (X6, XI0, XI6 and X23) with low XIAP mRNA levels. Four L clones
(L8, LI5, L23 and L24) were selected with mean XIAP levels similar to the mean of
the whole L group (11.6 ± 3.7). The mean XIAP mRNA level in the four selected
vector control cell lines was 12.7 ± 1.1, and percentage knockdown was calculated
relative to this. The knockdown clones show reductions of 93%, 82%, 83% and 87%
in XIAP mRNA for X6, XI0, XI6 and X23 respectively relative to the mean of the
XIAP levels in the four vector expressing L control group. The mean level of XIAP
mRNA of four selected clones in the L group (12.7 ± 1.1) was not significantly
different to the level in the parental cell line (15.3 ± 2.0, t-test p=0.07).
Figure 39: XIAP mRNA levels per lOng total RNA by qRT-PCR. Parental cell line HCT116,
luciferase expressing vector control (L prefix) and vector expressing short hairpin RNA to XIAP
(X prefix). Error bars show standard deviation from the mean for triplicate samples in the
experiment.
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XIAP protein levels by Western immunoblot confirmed knock down in the X clones
of 89%, 79%, 73% and 67% for X6, X10, X16 and X23 respectively relative to the
mean level in four L clones (0.435 ± 0.08) (Figure 40).
0.048 0.091 0.118 0.1G3 0.550 0.409 0.429 0.353
X6 X10 X16 X23 L8 L15 L23 L24
Figure 40: Western immunoblot using XIAP monoclonal mouse antibody (Stressgen).
Quantification performed with Image Quant software and corrected protein ratio XIAP/Actin
shown at early passage (p4). Percentage knockdown expressed relative to the mean level of
XIAP in the four vector controls (0.435 +/-0.08).
7.3.2 Stability of knockdown with cell passage
Stable knockdown at the mRNA level was maintained at passage 8 (Figure 41) in X6
(85%), XI6 (81%) and X23 (79%), however the mRNA levels in XI0 had risen to
only 59% knockdown.
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Figure 41: Average XIAP mRNA levels per lOng total RNA by qRT-PCR comparing early (p4)
and late (p8) passage of cells. Error bars show standard deviation from the mean for triplicate
samples in the experiment. XIAP levels are consistently high for the four L clones at p4 and p8.
XIAP levels are low at p4 and p8 for three of the X clones except for X10 where the XIAP levels
have risen at p8.
Stable knockdown was confirmed by protein quantification at passage 8 (Figure 42);
X6 90%, XI6 72% and X23 63%. These results are consistent with the early passage
data described above, however the protein levels in XI0 had increased to 49% XIAP
knockdown. Owing to the lack of long term stability of the construct in the XI0 cell
line at both the mRNA and protein levels, it was removed from cytotoxicity studies
in later chapters. A summary of percentage XIAP down regulation at the RNA and
protein levels at early and late passage is presented in Table 7.
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X6 X10 X16 X23 L8 L15 L23 L24
Figure 42: Western immunoblot using XIAP monoclonal mouse antibody (Stressgen).
Quantitation performed with Image Quant software and corrected protein ratio XIAP/Actin
shown at late passage (p8). Percentage knockdown expressed relative to the mean level of XIAP
in the four vector controls (0.430 +/-0.08).
mRNA p4 mRNA p8 Protein p4 Protein p8
X6 93% 85% 89% 90%
X10 82% 59% 79% 49%
X16 83% 81% 73% 72%
X23 87% 79% 67% 63%
Table 7: Summary of percentage knockdown in each of the X cell lines at the RNA and protein
levels at early and late passage.
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7.3.3 Microarray
The quality of the RNA extracted from the clonal cell lines by Agilent Bioanalyser is
shown in Figure 43. Two distinct 18S and 28S rRNA bands are clearly seen. The
Nanodrop spectrophotometer was used to quantify RNA before sending it for
microarray analysis and the A260/280 ratio was found to be between 1.94 and 2.12
(acceptable range 1.9 - 2.1).
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Figure 43: Agilent Bioanalyser RNA quality extracted from clonal cell lines at early (p4) and
late (p8) passage. For these samples the RNA integrity number (RIN) was 7.6 - 9.7. The
A260/280 ratio by Nanodrop spectrophotometer was 1.94 - 2.12.
Details of quality control measures can be seen in Table 8. 375' ratios for GAPDH
and beta-actin were 0.92 - 1.66 (target < 3). BioB spike controls were found to be
present on all chips, with BioC, BioD and CreX also present in increasing intensity.
When scaled to a target intensity of 100 (using Affymetrix MAS 5.0 array analysis
software), scaling factors for all arrays were within the 3 fold acceptable limit (0.575
- 1.020), as were background and mean intensities.










L8p4 0.575 45.74 0.445 0.95 1.25
L15p4 0.793 50.77 0.428 1 1.31
L23p4 0.727 47.78 0.442 0.95 1.17
L24p4 0.767 49.44 0.43 0.98 1.17
X6p4 0.893 45.25 0.427 1.04 1.08
X10p4 0.798 46.85 0.436 0.94 1.40
X16p4 0.859 48.56 0.440 0.93 1.14
X23p4 0.695 48.70 0.444 0.95 1.18
X6p8 0.843 46.42 0.436 1 1.54
X10p8 0.834 48.97 0.439 0.97 1.25
X16p8 0.884 52.68 0.431 1.05 1.31
X23p8 0.789 50.60 0.448 1.06 1.34
L8p8 0.824 46.74 0.447 0.98 1.20
L15p8 1.02 47.04 0.445 1.05 1.66
L23p8 0.732 43.43 0.459 1 1.35
L24p8 0.808 45.56 0.460 1 1.51
HCT116B 0.858 48.60 0.433 0.99 1.02
HCT116C 0.84 51.48 0.430 0.92 1.01
Table 8: Quality Control Data for 18 RNA samples on the Affymetrix HG U133 plus 2
GeneChip.
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Several groups of genes were investigated according to literature review and
potential relevance of known pathways, these are summarised in Table 9. Seven IAP
family members (NIAP, cIAPl, cIAP2, XIAP, survivin, apollon, livin) were
quantified; the eighth member of this family ILP2 was not represented on the
Affymetrix chip. Members of the bcl-2 family, the extrinsic pathway members and
other factors which have been reported as showing interactions with XIAP on
literature review (MURR1 (75), akt2 (92), smac/Diablo (106), XAF1 (81), htra2/omi
(136), apafl (88), GSPT1 (85) andNF-xB (71)) were also analysed.
IAi' FamiH | BCL2 Family Association with XIAP Extrinsic Pathway
NAIP BCL2 MURR1 TRAIL
CIAPl BAX AKT2 DR4
CIAP2 BAK1 smac/diablo DR5
XIAP BAD XAF1 FAS
survivin BCL2L1 htra2/omi FADD
appollon BCL2L2 APAF1 CASP3
livin BID GSPT1/Erf3 CASP7
NF-kB1 CASP8
CASP9
Table 9: The categories of gene analysed by microarray and the identified members of these
groups. Colours correspond to Figure 44, Figure 45 and Figure 46 below. XIAP is represented
in black.
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For the purpose of considering which genes were differentially expressed, a twofold
change was used i.e. -2 being a twofold down regulation of the gene and +2 being a
twofold up regulation of the gene. In Figure 44, Figure 45 and Figure 46 the X axis
represents log2 fold change, the two vertical lines represent ± 2 fold change in
expression. The Y axis is a negative logio transformation of the FDR (false discovery
rate) adjusted p-value; points above this line pass a p-value cut-off of <0.05 which
was considered significant. The genes of interest may therefore be found in the top
right and top left of the volcano plots.
The results in Figure 44 show that none of the genes of interest were significantly
changed when comparing the parental HCT116 cell line to the luciferase expressing
controls. In fact only 3 genes on the whole chip are significantly changed using our
criteria. This validates the L cell lines as a good reference for the XIAP knockdown
clones and therefore the parental FICT116 cell line was excluded from further
investigation.
Log2 Fold Change
Figure 44: Comparison between HCT116 cell lines (duplicate) and luciferase expressing controls
(four L cell lines) at early passage (p4).
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The results in Figure 45 show significant down regulation at 6 (out of a total 7) XIAP
probe sets (shown in dark blue) at early passage. There was no compensatory up
regulation in other members of the IAP family also shown in dark blue. BCL2 family
members, genes linked to the extrinsic pathway and other genes reported to be
associated with XIAP were also not significantly changed when comparing X with L
cell lines. There was one BCL2 family member (BCL2) which was up regulated
(green dots) however this did not reach statistical significance and it was only one
out of 8 BCL2 probe sets represented on the GeneChip. There are a number of other
genes which are significantly changed (grey circles), 9 up and 2 down. Further study
of these genes may provide insight into the regulation and function of XIAP but is



















Figure 45: Comparison of the four X cell lines and four L cell lines at early passage (p4).
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A significant down regulation of XIAP was seen in 3 out of 7 probe sets at later
passage (p8) in Figure 46. Again, none of the other genes of interest were
differentially expressed. Of the other genes on the GeneChip only 2 other (grey
circles) were significantly up regulated, these 2 genes were also significantly


















Figure 46: Comparison of the four X cell lines and four L cell lines at late passage (p8).
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XIAP fold changes and level of significance at the seven probe sets by Accession
Number on the Affymetrix GeneChip are compared in Table 10. The mean XIAP
fold change is greater at the p4 time point 4.3 ± 1.9 when compared to the p8 time
point 2.4 ± 0.6. One of the probes NM_001167 showed a fold change <2 which was
not statistically significant at both time points. The XIAP fold change at p4 is
comparable to the down regulation seen by qRT-PCR (described in Figure 39 and
correlated Figure 49), these are different techniques but both assess changes at the
mRNA level. There is a good correlation between the two techniques (Figure 49).
Accession Number Fold Change p4 p value Fold Change p8 p value
U32974 -2.73 0.03419 -2.45 0.18938
NM_001167 -1.66 0.13738 -1.29 0.61492
N30645 -4.25 0.00005 -2.60 0.01574
N30645 -5.24 0.00007 -2.39 0.18938
BF109251 -7.63 0.00027 -3.25 0.18938
AW675725 -4.51 0.00002 -2.45 0.01574
BE380045 -3.83 0.00007 -2.41 0.02554
Table 10: Microarray comparison by fold change and level of significance of XIAP levels of the
4X and 4L cell lines at seven probe sets (GenBank Accession Number shown) at early passage
(p4) and late passage (p8).
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7.3.4 Gene expression of IAP family members and related genes
Members of the IAP family cIAPl, cIAP2 and survivin were analysed by
quantitative RT-PCR. There is large variation in cIAP2 (15 fold) and survivin (34
fold) levels throughout the cell lines (Figure 47); cIAPl shows less variation (2 fold).






Figure 47: IAP family expression per lOng total RNA in clonal cell lines at early passage by
qRT-PCR. Error bars show the standard deviation from the mean.
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XAF1 expression (Figure 48) ranged between 0.01 and 0.05 for most clonal cell line
derivatives except L24 which, at 1.51, is beyond the scale of the graph. There is no
correlation between XIAP and XAF1 levels in this model.
Figure 48: XAF1 expression by quantitative RT-PCR per lOOng total RNA in early passage
clonal cell lines. Error bars show standard deviation from the mean. A Colo205 standard curve
was used due to relatively low expression of XAF1 in HCT116, therefore these results cannot be
directly compared with other qRT-PCR data.
The three other members of the IAP family cIAPl, cIAP2 and survivin were
analysed by qRT-PCR (Figure 47) and the results compared with microarray data in
order to validate the newer technique (Figure 49). The R2 values for these
correlations are XIAP 0.80 - 0.98, CIAPl 0.57, CIAP2 0.90 - 0.98, Survivin 0.90 -
0.94 (Table 11). There was good correlation between microarray and quantitative
RT-PCR data for three out of the four members of the IAP family investigated.
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CIAP1 shows a poorer correlation however there is only one probe set for this gene
and perhaps this highlights the need for multiple probesets on the GeneChip.
XIAP
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RT-PCR per ng RNA
Figure 49: Correlation of RT-PCR and Microarray data for four IAP family members at early
passage (p4). Each dot represents a cell line. Each line shows the correlation of the gene
expression by RT-PCR with a probe set on the Affymetrix Genechip.
For RT-PCR data the results are expressed as a mean value of three reactions per ng
total RNA then normalised to the parental HCT116 level. For Microarray data each
probe set is shown normalised to the HCT116 parental value.
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XIAP CIAP1 CIAP2 Survivin
R2 p value R2 p value R2 p value R2 p value
Ml 0.8031 0.0011 0.5661 0.0193 0.9843 <0.0001 0.9366 <0.0001
M2 0.9709 <0.0001 0.9039 <0.0001 0.9412 <0.0001
M3 0.983 <0.0001 0.9062 <0.0001




Table 11: R2 correlation values for RT-PCR data with microarray data, p value for slope of line
significantly non zero for Figure 49 above.
7.3.5 Cell Line Characteristics
7.3.5.1 Morphology
The morphology of the two cell lines L8 and X23 was compared by light microscopy
(Figure 50) at the optimal seeding density for each cell line, at the same passage on
the same day after seeding. The X23 cell line shows "spindle like" protrusions such
that the cells appear elongated. Survivin, a member of the IAP family, has been
shown to have role in mitotic cell division and spindle assembly (137) and it is
possible that XIAP has similar but yet unidentified properties. Geisbrecht et al
describe a role for dIAPl (drosophila inhibitor of apoptosis) in cell migration and
found that cells lacking this protein fail to migrate (138). In addition, smac, the
negative regulator of XIAP, inhibits cell motility and random migration at low cell
density (139).
shXIAP HCT116 cells 119
Chapter 7
Figure 50: Morphology of the L8 (top) and X23 (bottom) cell lines at late passage x20
magnification.
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7.3.5.2 Growth curves
The growth curves of the nine cell lines differed (Figure 51) with the X cell lines
growing at a slower rate than the L cell lines. Thus to produce the superimposed
growth curve necessary for cytotoxicity experiments the seeding density of each cell
line in 96-well plates differed. A greater number of X cells per well were required;
X6 4000, XI0 3500, X16 5000, X23 5000 cells per well compared to L8 3500, LI5
4000, L23 4000, L24 2500 L cells per well and HCT116 2000 cells per well. When
these seeding densities are adhered to, similar doubling times are seen (mean 21.7 +/-
1.36 hours) as shown in Table 12. The growth curve for HCT116 differs in that there
is a shorter lag phase before exponential growth. This could be explained by the
differences in growth media; the HCT116 cell line is grown without geneticin which












Figure 51: Growth curve by SRB assay at seeding density of 3500 cell per well. In order to
achieve a similar growth curve and doubling time for comparison between cell lines the number
of cells per well differs. Note the plating efficiency differs between cell lines.











X6 4000 22.9 0.72 2.22
X10 3500 22.2 0.60 1.11
X16 5000 23.3 0.81 3.42
X23 5000 21.6 0.52 3.3
L8 3500 21.5 0.73 0.98
L15 4000 20.6 0.61 1.27
L23 4000 23.2 0.62 0.9
L24 2500 19.3 0.40 0.28
HCT116 2000 20.5 0.69
Table 12: Growth characteristics (Doubling time, Plating efficiency and Floating cell fraction)
for each cell line at optimal seeding density.
7.3.5.3 Plating efficiency and Floating cell fraction
The plating efficiency varied across all cell lines examined (Table 12) therefore all
experiments were designed in order to avoid removal of growth media and the
resulting introduction of bias. The X cell lines have a higher floating cell fraction
(1.11 - 3.42%) compared to the L cells lines (0.28 - 1.27%), Table 12.
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7.3.5.4 Apoptosis
Annexin V - PI staining showed a higher percentage of early apoptotic cells in the
X23 cell line 10.2% compared to 6.5% in the L8 cell line (Figure 52). However, the
increased fraction of cells which stained positive for both annexin V and PI (10.4%
vs 5.9%) indicates that there was also a higher proportion of cells which have cell






Figure 52: Annexin V - PI staining with FACS analysis. The X23 cell line has a higher
percentage of early apoptotic cells which stain positive for annexin V (10.2% vs 6.5% in L8).
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The level of caspase activity in the cell lines was determined to investigate whether
stable XIAP knockdown leads to increased activation of the apoptotic pathway; a late
event. The levels of activated caspase 3/7 by ApoOne assay were unchanged when
comparing HCT116 (50 ± 11.6), L8 (57 ± 3.0) and X23 (46 ± 8.1), T-test p = 0.14
(Figure 53).
2 70 n 50 57 46
£
Figure 53: Caspase 3/7 activity minus background levels for untreated cells at the same seeding
density. There was no difference in baseline ApoOne caspase 3/7 activity between the cell lines.
Error bars represent standard deviation from the mean for three independent experiments.
The X23 cells could therefore be considered as "primed" to undergo apoptosis as the
early annexin V results suggest but the caspases have not been activated as seen in
the ApoOne assay.
shXIAP HCT116 cells 124
Chapter 7
7.3.5.5 DR5 membrane expression
The expression of TRAIL receptors (DR5) on the cell surface was quantified by flow
cytometry prior to performing experiments with the agonist rhTRAIL (Figure 54).
The results are compared to a leukaemia cell line (Jurkat) which is known to express
DR5. The median fluorescence for Jurkat cells was 30, HCT116 75, L8 91, X23 89
confirming that the receptor expression between the control cell line L8 and XIAP
knockdown cell line X23 was unchanged.
FL2-H
Figure 54: Cells stained with phycoerythrin conjugated DR5 antibody and analysed by flow
cytometry (X23 purple, L8 pink, HCT116 blue). Jurkat cells (orange) used as positive control.
There is similar DR5 expression in L8 and X23
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7.4 Discussion
An isogenic model has been developed from derivatives of the HCT116 colorectal
cell line where the only genetic difference between the cell lines is the XIAP
expression. There is down regulation of 82-93% at the mRNA level which is
generally stable (79-85%) over the course of four passages; 4 weeks of cell growth
with the exception of the XI0 clone which would appear to have lost the vector
construct. When the same vector construct (provided by Aegera Therapeutics Inc)
expressing shXIAP was used in the breast cell line MDA-MB-231, 85% reductions
in the mRNA level and 85-95% reductions in the XIAP protein level were seen (41).
The X23 and L8 cell lines were selected for further study based on the results of in
vivo xenograft growth studies which will be discussed further in Chapter 9.
Quantification of protein levels will be less accurate as the technique relies on image
analysis and is not referenced to a standard curve as in the qRT-PCR technique.
There are limitations to using a stable knockdown model; in this study investigation
of XIAP levels was limited to 8 passages and therefore further experiments were
only valid if performed within this timeframe. McManus et al (41) noted stable down
regulation of XIAP over 24 passages of the knockdown cell lines. An alternative is
transient siRNA transfection, one study (135) has shown 80-90% XIAP down
regulation at the mRNA level in 3 canine tumour cell lines at 72 hours post
transfection with lipofectamine. The disadvantage of transient models is the short
lived dynamic effect and potential acute gene changes associated with the use of
transfection reagents, as discussed in Chapter 5. A further alternative is an inducible
"Tet-on" system in which the gene expression change may be switched on by adding
tetracycline to the cell growth media. This technique has recently been developed in
the HCT116 colorectal cell line (140) and has the advantage of a stable cell line in
which to investigate the consequences of gene manipulation. However, these systems
are technically difficult to establish.
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The microarray study described here shows that a large number of transcripts may be
quantified in a short period of time. It is essential that the RNA is good quality as the
technique is very sensitive and the quality control measures must be adhered to. Here
the expression of a relatively small number of genes has been assessed; however, a
further analysis could be performed to identify potential new associations with XIAP
which have not yet been reported.
With large volumes of data generated by microarray it is necessary to set a threshold
above or below which a change in gene expression is considered significant. The fold
change (+/-2) and the p value selected (<0.05) are arbitrary values based on
experience in bioinformatics and statistics. It is entirely possible, however, that the
expression of key genes involved in the cell survival apparatus need only small
changes in expression to trigger dramatic changes owing to complex downstream
pathways amplifying their effects. Such genes are in danger of being overlooked
when using arbitrary thresholds to analyse the microarray data and it may be more
important to consider genes which remain significantly changed at p4 and p8
regardless of the fold change. In this data set there are only 6 genes with significantly
altered expression at both time points - three XIAP as mentioned above, two others
which reached the fold change cut off and one whose fold change was -1.99 hence
did not reach the original criteria. This gene may be worth considering as it could be
argued that a sustained change (which is statistically significant) is as biologically
significant as a magnitude change. This highlights a pitfall with interpreting
microarray data: it would be easy to miss biological effect as one is only detecting
gene expression change. Some genes may only require small magnitudes of change
in order to produce functional change within the cell. Microarray should therefore be
used as a large scale screening tool and functional characterisation studies remain
important when assessing biological effect within a cell.
The results described above confirm specific and stable down regulation of XIAP
with no impact on the related genes identified on literature review. In a breast cancer
model of stable (41) XIAP knockdown using the same vector constructs no
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compensation of other IAP family members was seen in concordance with our
microarray and qRT-PCR data. The XIAP knockout mouse (76) shows compensatory
up regulation in CIAP1 and CIAP2 at the protein level. As XIAP is the most potent
caspase inhibitor in the family of IAPs, in a model where a small amount of XIAP
remains, it is likely that this small amount is enough to carry out a functional role.
There was good correlation between microarray expression and qRT-PCR data
therefore validating the newer microarray technique. The four XIAP knockdown cell
lines developed here may therefore be confidently used for cytotoxicity studies in
vitro over many weeks. In vivo xenograft establishment and XIAP mRNA levels are
discussed in Chapter 9.
There have been concerns that down regulation of XIAP would be compensated by
increases in other members of the IAP family implying redundancy of the target. In
the XIAP deficient mouse (76) there were increases in cIAPl and cIAP2 protein
levels and this may be the case in a model with complete XIAP loss rather than 80%
down regulation. In a breast cancer model of stable (41) XIAP knockdown no
compensation of other IAP family members was seen; this is in concordance with the
qRT-PCR data presented here.
Here we report differences in the growth pattern of shXIAP expressing cells. Our
data show that the XIAP deficient cell lines grow at a slower rate than their luciferase
expressing counterparts. The HCT116 grows in a different manner which may be due
to the absence of geneticin in the media or that it does not carry the short hairpin
expressing vector. For comparison of the effects of XIAP down regulation it is
therefore more accurate to compare X with the L control rather than the parental
HCT116 cell line data. The knockdown cells also detach from a cell culture plate
more easily as seen by the higher floating cell fraction. It is possible that stable down
regulation ofXIAP causes subtle phenotypic changes which have yet to be identified.
When the XIAP knockout mouse was developed (76) there were initially thought to
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be no phenotypic changes but since then differences in copper metabolism (75),
mammary gland development (141) and signal transduction cascades (54) have been
documented. This is to be expected as it is now known that role of XIAP extends
beyond caspase inhibition; there is evidence for effects on cell division, cell cycle
progression and signal transduction (3).
The Death Receptor 5 (DR5) expression in these cell lines was unchanged which is
important to document prior to conducting experiments with TRAIL. There have
been reports of the death receptors being up regulated in certain situations such as
radiation treatment (34) and the levels ofDR4 and DR5 have also been noted to vary
across colorectal cell lines (34). Low levels of DR4 expression were seen in the
HCT116 though DR5 was highly expressed. However, there was no good correlation
between expression of the DR5 receptor and cytotoxicity with the DR5 agonist
monoclonal antibody (142).
AV-PI assay results showed an increased early apoptotic fraction in the X23 cell line
suggesting that the cells have commenced the journey along the apoptotic pathway
but the effectors of apoptosis are not yet activated as we report similar levels of
caspase 3/7 activity across untreated X and L colorectal cell lines. Given that initial
studies ofXIAP described its ability to directly inhibit caspases (55) it is necessary to
examine whether XIAP down regulation alone increases caspase activation.
McManus et al {41) found no increase in caspase 3 or 9 activity in untreated stable
XIAP knockdown breast cancer cells consistent with our data. There have been
reports of XIAP down regulation alone inducing apoptosis (95); in transient XIAP
inhibition with antisense there was an increase in apoptosis in a lung cancer model in
vitro compared to a missense control. This suggests that the effect may be due to the
acute short term nature of the knockdown.
Current clinical methods for down regulation of XIAP - by antisense - are given as
an infusion over seven days (as described in Chapter 2). The tissue half life of the
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drug is known to be long (many days) though the plasma half life is only a few
hours. The model developed here therefore draws more parallels with the clinical
situation where the goal is to cause XIAP tissue levels to decrease for a significant
period of time as compared to transient transfection in cell line models which may
cause cellular changes related to the transfection agents used.
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7.5 Conclusion
A colorectal cancer HCT116 cell line model has been developed using short hairpin
RNA targeting XIAP stably expressed in the HCT116 cell line model. XIAP was
down regulated at the mRNA and protein levels and this knockdown was maintained
over at least 4 weeks. The 80% down regulation was similar to levels which may be
achieved clinically with antisense targeted to XIAP. There was no compensatory up
regulation of other members of the IAP family (cIAPl, cIAP2 and survivin) or
XAF1, the negative regulator ofXIAP.
The microarray technique was a powerful tool for identifying gene changes in this
model of XIAP down regulation. The results confirm down regulation of XIAP at
early and late passage although some of the fold change effect was lost over time.
The data correlates well with the RT-PCR data therefore validating the newer
technique. There were no compensatory changes in genes currently documented to
have an association with XIAP function. Therefore a colorectal cancer model has
been developed using isogenic cell lines which differ only in the XIAP status at
clinically relevant levels.
The in vitro characterisation of these cell lines show differences in cell growth,
plating efficiency and morphology in the XIAP deficient cell line. The functional
caspase 3/7 activity levels and the DR5 receptor expression were similar when
comparing X23 and L8 cell lines.
Further studies will investigate the isogenic cell line developed in vitro and in an in
vivo mouse model. This model may be used to study the role of XIAP down
regulation in combination with classical cytotoxic agents to identify useful potential
clinical combination therapies.
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8 In Vitro Cytotoxicity in stable XIAP knock down cells
8.1 Introduction
The clonal cell lines developed in Chapter 7 were investigated in vitro for cytotoxic
response to chemotherapeutic agents and the results are described here. Classical
agents used in the treatment of colorectal cancer; camptothecin, 5-FU, oxaliplatin
and y radiation were used in the stable XIAP knock down model in an attempt to
identify potential combination strategies for further development.
In order to identify whether XIAP plays a role in resistance mechanisms to drugs not
usually used in the treatment of colorectal cancer, treatment with paclitaxel and
docetaxel were investigated. These agents have shown efficacy combined with XIAP
down regulation in lung, prostate and breast cancer models (40, 41) and therefore the
mechanism may be related to a class effect of the taxanes rather than a feature of
colorectal cancer.
rhTRAIL (recombinant human TNF-related apoptosis-inducing ligand) is known to
stimulate apoptosis by directly activating the extrinsic apoptotic pathway (see Figure
1, Chapter 1). This allows a targeted approach to the XIAP mechanism of resistance
without the potential complications of other less specific chemotherapeutic agents.
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8.2 Results
8.2.1 Response to rhTRAIL
As a preliminary study all clonal cell lines were exposed to rhTRAIL over a
concentration range for 24, 48 and 72 hours to investigate the optimal dose and time
point for further experiments (Figure 55). For the XI0 and L24 cell lines the IC50 is
>100ng/ml. Given the variation in cytotoxicity over time throughout the cell lines it
was prudent to select a pair which had similar characteristics. The IC50 was constant
over time for the X23 and L8 cell lines and therefore these were selected for further
studies using rhTRAIL. McManus et al (41) assessed cell viability at the 20 hour
time-point after TRAIL treatment in a breast and lung cancer model and it was
therefore decided to perform cytotoxicity assays at the 24 hour time-point in
subsequent studies. The selection of L8 and X23 was also based on the in vivo
growth curves which were performed simultaneously (see Chapter 9) in order to
allow translation to an animal model.
Cell Line
Figure 55: Clonal HCT116 cell lines treated with rhTRAIL over a concentration range (0.01 -
100 ng/ml). Cell viability assessed by MTT assay at three time points (24, 48, 72 hours). For the
X10 and L24 cell lines the IC50 is >100ng/ml.
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The cytotoxicity curve for a representative experiment is shown in Figure 56. The
cells were seeded at the optimal seeding density, treated with a range of rhTRAIL
concentrations (0.01 - lOOng) and cell viability estimated by the MTT assay. The
mean IC50 of three experiments for X23 was 0.39 ng/ml (SD 0.16) compared to mean
IC50 for L8 1.31ng/ml (SD 0.42). The X23 cell line shows a statistically significant
(p<0.05 by t-test) 3-fold increase in cytotoxicity when compared to the L8 cell line.
125-1








X23 0.39 * 0.16
L8 1.31 0.42
Figure 56: Cells treated with range of rhTRAIL (0.01 - lOOng) concentrations for 24 hours.
Viable cells calculated relative to control by MTT assay. Graph shows representative
experiment, error bars show standard deviation of the mean.
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To confirm that loss of cell viability was due to the activation of the extrinsic
apoptotic pathway caspase 3/7 activity was estimated with the ApoOne assay. Cells
were seeded at the optimal seeding density for 24 hours prior to treatment with
rhTRAIL at 5ng/ml for 2.5 hours. There is a two fold increase in caspase 3/7 activity
in the XIAP knockdown cell line (Figure 57); X23 186 RFU (SD 20.2) compared to
L8 87 RFU (SD 19.7), p<0.004 by t-test.
Figure 57: Cells treated with rhTRAIL 5ng/ml for 2.5hrs. Difference (treated - untreated) in
caspase 3/7 activity by ApoOne assay across cell lines. Error bars show standard deviation from
the mean for three independent experiments.
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8.2.2 Response to radiotherapy
As colorectal cancer is commonly treated clinically with radiotherapy we
investigated the effect of this treatment modality in our XIAP knockdown model.
The cells were seeded at the optimal seeding density and allowed to attach overnight
prior to treatment with a single fraction of y radiation over the dose range 0-16 Gy.
The cells were incubated for 120 hours (5 days) prior to estimation of cell number by
SRB assay. The radiotherapy dose for 50% survival of the 3 X clones was X6 9.7,
X16 11.5, X23 10.2 Gy compared to L8 12.2, L15 14.3, L23 13.4, L24 13.7 Gy for
the 4 L clones (Figure 58). Mean 50% survival value for X clones is 10.5Gy (SD
0.93) and L clones is 13.4 Gy (SD 0.88), p <0.02 by t-test. Radiotherapy studies
showed approximately 20% increase in sensitivity for the X cell lines compared to
































Figure 58: Effect of radiotherapy over a dose range of 0-16 Gy for cell lines by SRB assay. Error
bars show standard error of the mean for 3 individual experiments. There is a significant
increase in sensitivity to radiotherapy (t-test p<0.02).
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8.2.3 Response to cytotoxic agents
Due to the relatively long drug exposure described by McManus et al (41) (72 hrs,
three doubling times) a lower cell number was plated in order to be within the
validated range for the SRB assay. However, in order for these cells to be growing
exponentially, a 72 hour incubation was required prior to treatment (see growth
curves Chapter 7).
Preliminary data from cytotoxicity experiments with 5FU and oxaliplatin where cells
were treated at the IC50 dose are shown in Table 13. These data showed no benefit of
XIAP down regulation across the X and L cell lines and therefore full cytotoxicity
studies were not pursued.
% cells X6 X16 X23 L8 L15 L23 L24
5FU
5pM
46.0 53.2 51.3 65.2 66.0 43.9 63.6
Oxaliplatin
lpM
44.7 78.0 57.7 68.7 81.7 53.4 68.3
Table 13: Clonal cell lines treated with 5FU and oxaliplatin at the IC50. Percentage cells by SRB
assay.
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Cytotoxicity studies with camptothecin (Figure 59) showed no consistent difference
in the IC50 of the X cell lines compared to the luciferase controls, the two groups
overlapped in terms of IC50 giving a mean of 62.2nM (SD 43.3) for three X cell lines
























Figure 59: Cytotoxic effect on clonal cell lines treated with camptothecin (0.5 - 500nM) for 72hrs
by SRB assay. Error bars show standard error of the mean for 3 individual experiments.
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The mean paclitaxel IC50 for three X cell lines was 5.5 (±0.35) nM compared to >8.1
nM for L cell lines. For docetaxel the mean IC50 was 2.2 (±0.56) nM for X cell lines
and >5.9nM for L cell lines (Figure 60). Therefore at least a 2-fold increase in
sensitivity to docetaxel treatment was identified in the XIAP knockdown cell lines.
As the percentage cell death did not reach 50% in some of the L cell lines (L23, L24)
at the highest treatment dose, an IC50 value cannot be accurately calculated and this





























Figure 60: Cytotoxic effect on clonal cell lines treated with paclitaxel (1 -lOOnM) and docetaxel
(0.5 — 50nM) for 72hrs by SRB assay. Error bars show standard error of the mean for 3
individual experiments.
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8.3 Discussion
These data show a threefold increase in TRAIL cytotoxicity in vitro in a XIAP
knockdown model. Cummins et al (131) were able to demonstrate a marked increase
in sensitivity to TRAIL-mediated apoptosis and a corresponding decrease in
clonogenic survival in a XIAP null HCT116 model. Our results therefore reproduce
this effect though to a lesser degree and this may be explained by the 80% knock
down of XIAP seen here compared with the complete knockout seen in the null
system. In breast and pancreatic cancer cell lines (41) using the same short hairpin
vector with similar levels of XIAP down regulation, a 100-fold increase in TRAIL
cytotoxicity was seen. We could therefore hypothesise that a greater decrease in
XIAP levels is required in a colorectal cancer model.
To investigate caspase activation in the two selected cell lines an earlier time-point
was chosen as this is an earlier event in the apoptotic cascade. Cummins et al (131)
were able to demonstrate cleaved caspase 3 at the 3 hour time point in the HCT116
colorectal cancer cell line. McManus et al used the identical rhTRAIL product at a
dose of 5ng/ml therefore these conditions were also chosen for this study (41). A two
fold increase in caspase 3/7 activity was demonstrated which confirms that the
increase in TRAIL cytotoxicity is due to activation of the apoptotic cascade. A study
of TRAIL receptor agonists in combination with radiotherapy in colorectal cancer
models has shown promising results in vitro and in vivo (34).
Here we describe a 20% increase in sensitivity to y radiation in the XIAP knockdown
HCT116 cell line compared to the controls. Marini et al noted that a single fraction
of y radiation induced less than 10% apoptosis in the HCT116 wild type cell line.
HCT116 was relatively resistant to radiotherapy compared to two other colorectal
derivatives COLO205 and HCT15 though they used a lower dose of lOGy (34).
Radiotherapy studies performed with antisense oligonucleotides to XIAP transiently
transfected in vitro into non small cell lung cancer cell lines led to a 20% increase in
apoptotic cells after treatment with 2 Gy radiation (95). The differences in results
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may therefore be explained by the differing sensitivities of cell lines and tumour
types to y radiation.
When treated with cytotoxic agents commonly used in the clinical treatment of
colorectal cancer (5FU, camptothecin and oxaliplatin) there was no significant
difference when comparing three X with four L cell lines. In the XIAP null system
pilot experiments showed "small differences in cytotoxicity between XIAP null and
wild type HCT116 cells when treated with cytotoxic agents such as 5FU" (Personal
communication F. Bunz) (131). This implies that the sensitivity of these drugs is
independent ofXIAP in the HCT116 model.
Our data show at least a two fold increase in cytotoxicity of paclitaxel and docetaxel
in the XIAP deficient cell lines. There is evidence that XIAP knock down sensitises
to taxane therapy in prostate and lung cancer models (40) and the evidence presented
here would concur. Taxanes are commonly used clinically in the treatment of both
prostate and lung cancer but not colorectal cancer therefore this may provide a new
therapeutic option. The effect may be due to the mechanism of action of taxanes
rather than the characteristics of the tumour types. Chkl, a kinase involved in the
DNA damage checkpoint response, has been shown to bind the BIR3 domain of
XIAP during mitosis (143). This provides some evidence of cross-talk between cell
cycle control and apoptosis although the precise mechanism remains to be clarified.
Paclitaxel has been shown to induce caspase 10 dependent apoptosis (144) which is a
component of the extrinsic pathway (involving the TRAIL receptors DR4 and DR5).
It may be useful to investigate whether the effects of XIAP are more dependent on
the extrinsic rather than the intrinsic pathway which is commonly associated with
cytotoxic drugs. Another theory, continuing the theme of a threshold effect, is that
treating with drugs known to be active in colorectal cancer does not show
sensitisation because they have already crossed the threshold. Other drugs such as the
taxanes may not have reached that threshold and therefore down regulating XIAP is
effective.
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A Phase 1 clinical trial is underway in solid tumours combining XIAP Antisense
(Aegera Therapeutics Inc) and docetaxel (National Cancer Institute of Canada
Clinical Trials Group). However, with such a narrow therapeutic index in colorectal
models, it is unlikely these treatments will be of additional clinical benefit. Future
work should focus on targeted agents such as rhTRAIL which directly stimulate the
extrinsic apoptotic pathway. One such agent, a death receptor agonist, is in early
clinical trial (145) and may show promise in combination with strategies to down
regulate XIAP.
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8.4 Conclusion
The XIAP deficient cell line X23 shows a 3-fold increase in sensitivity to rhTRAIL
compared to L8. A 20% increase in sensitivity to radiotherapy and at least a two fold
increase in sensitivity to docetaxel were seen in the X relative to the L cell lines.
Further studies with these agents in an in vivo model are therefore warranted.
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9 shXIAP Cell Lines in a Mouse Xenograft Model
9.1 Introduction
The initial in vitro and in vivo studies with XIAP antisense (AEG35156) failed to
show a reproducible effect compared to the missense control (AEG35187) as
described in Chapters 5 and 6. Therefore to establish whether down regulation of
XIAP was a valuable strategy in colorectal cancer stable knockdown cell lines were
developed as described in Chapter 7. This allowed an opportunity to test the efficacy
of classical chemotherapeutic agents in combination with low XIAP levels in an
isogenic system. The in vitro results of these studies are described in Chapter 8 and
based on these data the model of stable XIAP knockdown was further developed for
use in vivo.
The xenografts were established in female nude mice and growth pattern monitored
prior to extraction of xenograft RNA to confirm the levels of XIAP and persistence
of its down regulation in this model. Other lAPs and XAF1, the endogenous inhibitor
of XIAP, were also investigated. Definitive chemotherapeutic studies with docetaxel
were then performed to assess the effectiveness of a potential combination approach
in colorectal cancer.
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9.2 Results
9.2.1 In vivo xenograft establishment of clonal cell lines
All eight of the vector containing cell lines were successfully established in vivo
(Figure 61A). In this model the growth pattern differed from the in vitro results as
described in Chapter 7 Figure 51. Here, L8 and L23 grew faster than L24 and LI5
which had a longer lag phase. The X clones had intermediate growth rates. The eight
cell lines could be divided into two groups with a shorter (L8, L23, X23 and XI6) or
longer phase before exponential growth (X6, XI0, LI5 and L24). Therefore one X
and one L cell line were selected for further investigation to overcome these
difficulties. L8 and X23 had similar growth curves in this model, the growth of the
individual xenografts is presented in Figure 6IB, and were therefore selected as the
pair of cell lines for chemotherapeutic studies in order to eliminate bias in
comparison of cell growth patterns.
The take rate of the xenografts may be defined as the percentage of xenografts
reaching a volume of 0.150cm by day 26. For the luciferase expressing cell lines
these were L8 100%, LI 5 60%, L23 100%, L24 70% and for the shXIAP expressing
cell lines X6 100%, XI0 60%, XI6 67%, X23 90%.























Figure 61: In vivo establishment of HCT116 XIAP knock down cell lines and luciferase
expressing controls. A: Mean Volume (cm3) and standard deviation for each group over time
(days) with "no take" xenografts excluded. B: Growth curves for each individual xenograft in
the L8 and X23 groups to show range of volumes.
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9.2.2 Gene expression in xenografts
RNA was extracted from two xenografts (left and right flanks) in each cell line from
the above establishment study, during the extraction process the tumours were noted
to be cystic. This observation was not confined to either group of X or L cell lines
though may explain some of the inconsistencies in growth. XIAP mRNA levels were
investigated after 26 days in vivo growth (Figure 62). There was good correlation of
the XIAP levels on the left compared to the right flank of each animal in all cell
lines. The XIAP knockdown was X6 76%, XI0 57%, XI6 67%, X23 46% when the
mean of left and right flank XIAP levels were expressed as a proportion of mean
XIAP level in the eight samples of L clones (10.5 +/- 1.2). This implies that the X
cell lines continue to express the short hairpin RNA despite the absence of G418
selection medium although there is less XIAP down regulation when compared to the
in vitro model. A comparison of mean X23 and L8 XIAP levels, 5.6 and 10.1
respectively, shows 44% knockdown. The X23 cell line had the highest XIAP level
of all the X lines which may be insufficient knockdown.
Figure 62: Mean XIAP mRNA levels by qRT-PCR from left and right xenografts of a single
animal after 26 days of growth. Error bars show standard deviation for the triplicate RT-PCR
reaction.
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mRNA levels of three other members of the IAP family were investigated - CIAP1,
CIAP2 and survivin (Figure 63). Comparison of the 4 X with 4 L clones revealed no
significant differences in expression of any of these three endogenous inhibitors of
apoptosis. In particular comparison of X23 and L8 showed similar IAP levels


























Figure 63: Other IAP family members mRNA levels by qRT-PCR. RNA extracted from right
flank of xenograft on day 26. Error bars show standard deviation of the mean.
XAF1 levels cannot be directly compared with levels of the other IAPs as a different
cell line was used for the standard curve in the qRT-PCR reaction (Figure 64). There
is a tenfold variation in the XAF1 levels throughout the samples in this model which
varies throughout the X and L cell lines. In particular there is more than a 5 fold
difference in X23 and L8 levels, 29.0 and 5.5 respectively, which was not seen in
vitro and may be functionally significant.


























X6 X10 X16 X23 L8 L15 L23 L24
Figure 64: XAF1 RNA levels in lOOng total RNA by RT-PCR using COLO205 standard curve.
Error bars show standard deviation of the mean for the triplicate RT-PCR reaction.
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9.2.3 Clonal cell lines treated with docetaxel in vivo
For this study tumours were implanted on day -7 and the tumours were randomised
by volume on day 0. There were 10 tumours per treatment group and 20 tumours per
control group. The mice were treated with intraperitoneal docetaxel 5mg/kg on days
0, 4, 8, 11. Tumour volumes prior to randomisation (Figure 65) show no bias within
the L8 groups and the X23 groups. However, there was a difference between the L8
and X23 groups which was not anticipated from the establishment study. This may
be explained by the growth rates prior to randomisation (Figure 66); between day -5
and -3 the shXIAP expressing cell lines slow compared to the luciferase expressing
cell lines. After randomisation (Day 0-2) the X23 group grows faster than the L8
group. This may have an impact on the initial response to treatment as the xenografts
are in different phases of growth.
□ L8 control




Figure 65: Pre-Treatment volumes prior to randomisation (Day 0). L8 is luciferase expressing
cell line and X23 is shXIAP expressing cell line. Error bars show standard deviation from the
mean for the group.
shXIAP cells In Vivo 150
Chapter 9
—*— L8 control
- - * — L8 docetaxel 5mg/kg
—*—X23 control
- - - -X23 docetaxel 5mg/kg
Figure 66: Growth rate of clonal cell line xenografts prior to randomisation. Error bars show
standard error of the mean.
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In the docetaxel treated xenografts (Figure 67) there was slowing of growth in the
treated groups but this was not significant when compared to the control groups. As
treatment progressed the L8 treated group grew more slowly than the X23 group
though again this was not statistically significant.
Docetaxel Treated Xenografts
—♦— L8 control
- • * ■ - L8 docetaxel 5mg/kg
—*—X23 control
X23 docetaxel 5mg/kg
Figure 67: L8 and X23 xenografts treated with docetaxel 5mg/kg on days 0, 4, 8,11. Error bars
show standard deviation from the mean for the xenografts in that group.
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9.3 Discussion
In this xenograft model the growth patterns differed from those in vitro where the X
cell lines grew more slowly than their L controls (see Chapter 7). This may be due to
differences in three dimensional structure in a xenograft compared to cells growing
on a plate where the growth is two dimensional. The in vitro studies implied that
more X cells were required to form the same growth curve and therefore the cell-cell
interaction may be important. Another potential mechanism is that xenografts will be
hypoxic relative to cells grown in tissue culture and therefore perform differently
under these conditions. An end point of these studies was tumour volume but this
does not necessarily equate to cell death. During this study tumours were noted to be
cystic and further investigation may be useful to collect further samples for
assessment of apoptosis.
The two cell lines selected for further study (L8 and X23) had good take rates which
aids planning of further animal experiments in order to predict the numbers required.
Maintenance of XIAP knockdown at the RNA level is important to assure that the
model remains stable over a period of time which is sufficient to perform further
studies. The day 26 time point used in this study is well beyond that used in the
chemotherapeutic studies described below and therefore maintenance ofXIAP down
regulation is validated in this xenograft system. The degree ofX23 XIAP knockdown
(46%) is less than is observed in the in vitro model (88%) which then decreased to
68% at passage 8. Given that the XIAP knock down in the X cell lines reduces over
time following passage (seen also with microarray) it is perhaps not surprising that
the in vivo model also loses a little of its XIAP down regulation when established as
a xenograft. Further experiments to quantify XIAP mRNA levels in the short hairpin
expressing cell lines over time in this xenograft model would also identify whether
the effect decreases.
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CIAP1, CIAP2 and survivin levels are similar between cell lines and do not appear to
be associated with XIAP status. The levels of these three IAPs remain unchanged in
breast cancer cells containing the identical vector as described by McManus et al
(41) therefore our studies confirm these results in a second cell line from an
alternative tumour type.
In this model it is relevant to consider the functional significance of XAF1 levels
which are higher in the X23 cells which have decreased XIAP at the RNA level.
XAF1 antagonises the anti-caspase activity of XIAP and reverses the protective
effect ofXIAP over expression by sequestration of XIAP in nuclear inclusions (81).
Therefore high levels of XAF1 may enhance the effect of XIAP knockdown in the
X23 cells, further increasing caspase activation. XIAP RNA levels would be similar
as the total amount present has not changed but the cellular localisation prevents its
function. If that were the case then perhaps the growth of X23 xenografts would be
seen to slow, therefore it is likely that there are other important mechanisms which
have not been investigated here.
In the chemotherapeutic study with docetaxel treatment the untreated groups had to
be sacrificed on Day 10 before the end of cytotoxic treatment (Day 11). This leaves
the later part of the experiment uncontrolled; however no significant difference was
seen between the docetaxel treated groups. This may be due to the relative lack of
XIAP down regulation in this model (46%, compared to 70-80% in vitro) or that a
two-fold increase in cytotoxicity described in vitro for taxanes (Chapter 8) is not
sufficient to translate to the in vivo system.
Our in vitro studies suggested that TRAIL may be a novel potential targeted therapy
and further studies could be performed to explore this in an animal model.
Radiotherapy is another potential therapeutic combination and could be developed
though prior optimisation of the fractionation schedule would be required.
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9.4 Conclusion
All eight short hairpin expressing cell lines may be established in an in vivo
xenograft model, the L8 and X23 cell lines showing a similar growth pattern. XIAP
knock down was maintained at the mRNA level for 26 days after implantation
though the down regulation was less than that seen in vitro. There was no change in
the levels of CIAP1, CIAP2 and survivin across the eight cell lines but XAF1 was
increased in X23 compared to L8 which may be functionally relevant. Treatment of
X23 and L8 xenografts with docetaxel showed no significant differential effect on
growth.





The aim of this project was to determine whether XIAP down regulation alone, or in
combination with other therapeutic agents, is a potential treatment for patients with
colorectal cancer. To achieve this aim, the following studies were undertaken and
have been discussed in this thesis.
• The characterisation of colorectal cell lines according to p53, MLH1 and
XIAP status.
• The effects of transient transfection of XIAP antisense (AEG35156) in vitro
as a method ofXIAP down regulation.
• The anti-tumour efficacy and pharmacodynamic effect of AEG35156 in vivo
in a colorectal cancer xenograft model.
• The development and characterisation of stable XIAP knock down cell lines
using short hairpin RNA.
• The in vitro response of stable XIAP knock down cell lines to therapeutic
agents.
• The establishment and treatment of shXIAP-expressing cell lines as
xenografts.
The HCT116 cell line is mismatch repair deficient (MLH1-) but has a normal
functioning p53. Mismatch repair deficiency is a feature seen in 15% of patients with
colorectal cancer (146) and has been reported to be associated with resistance to
certain chemotherapeutic agents (130). It expresses XIAP at levels similar to the
other cells in the colon cancer panel we used and is up regulated compared to normal
tissue. It was particularly useful for my studies as it is a well characterised cell line; it
grows well in vitro and in vivo and can be readily modified. Experimental results can
also be compared with those generated using HCT116 XIAP null cell lines, in which
Cummins et al demonstrated enhanced sensitivity to TRAIL (131).
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A transient transfection method was used in the HCT116 colon cancer cell line and
achieved 81% down regulation of XIAP mRNA using AEG35156. However, in the
same experiment, down regulation (69%) of XIAP mRNA was also seen with the
missense compound, AEG35187. LaCasse et al had also noted a reduction of up to
22% in XIAP mRNA levels with a non-sense control (AEG35185) indicating a non
specific effect of the oligonucleotides (40). The use of a different control
oligonucleotide may explain the magnitude of the difference in non-specific effect. It
is essential to include control oligonucleotides in all experiments to assess whether
the oligonucleotide is functioning by the prescribed mechanism i.e. complementary
base pairing of the antisense to the XIAP mRNA. In the cytotoxicity experiments
reported in this thesis, no significant therapeutic benefit of antisense over missense
was seen; both showing a maximal cytotoxic effect of approximately 50% at
concentrations greater than 400nM (one day protocol) and approximately 80% at
concentrations greater than 200nM (two day protocol). These results suggest that
AEG35156 is acting via an alternate mechanism other than RNase H degradation of
the mRNA-antisense complex.
In order to achieve specific down regulation of XIAP only with the antisense (and
not missense) a one day transfection at 400nM could be performed however the
knockdown seen in this case is only 33%. Investigation of stimulation of the extrinsic
apoptotic pathway with TRAIL following 33% XIAP down regulation does not
confer a significant increase in apoptosis when compared to the missense control.
Combination studies with other recognised cytotoxics are also unlikely to be
effective with this level of selective down regulation of XIAP at the mRNA level.
Therefore, it was decided to develop a stable siRNA model ofXIAP knockdown and
this will discussed later.
In an initial in vivo experiment, AEG35156 was associated with a significant effect
on tumour growth in HCT116 xenografts compared to the missense control
AEG35187, but subsequent studies did not confirm this. Weight loss was also
observed in the antisense group identifying some toxicity in the animals. In vivo
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efficacy studies were also performed with other colorectal cell lines (COLO205,
HCT15, HT29 and SW620) but these results were not encouraging. It would
therefore be difficult to justify single agent usage in colorectal cancer based on these
studies. Lacasse et al have reported a 60% reduction in tumour volume in vivo in the
LS174T colorectal cancer model (40). It would be interesting to obtain and establish
the LS174T cell line to identify whether these data can be reproduced and compared
with local HCT116 data.
Pharmacodynamic assays were performed in in vivo studies in the HCT116 xenograft
model and mouse liver and tumour were analysed. Antisense directed against human
XIAP caused mRNA target knock down in mouse liver despite a 3 base pair
mismatch. Mouse liver XIAP down regulation of 43% appeared to be maximal 3
days after end of treatment. The effects of XIAP down regulation in mouse liver are
cumulative in our study with 42% knock down seen 24 hours after 3 weeks of
treatment. The tissue half life of AEG35156 is known to be approximately 14 days
(personal communication, Aegera Therapeutics) and therefore these results would be
consistent.
More concerning is the potential lack of specificity of the antisense and further
pharmacodynamic studies would be useful to determine this. XIAP down regulation
was not seen in the HCT116 human xenografts for which the mRNA sequence was
designed although this could be due to the lack of drug delivery to the xenograft in
this model. In clinical studies antisense molecules are known to cause liver
transaminitis (112) which is thought to be a backbone effect of the oligonucleotide
but here they also appear to be causing XIAP down regulation when the mRNA
sequence was not specifically designed for this. The lack of specificity was also
demonstrated in the in vitro studies where missense was shown to down regulate
XIAP. This should be considered when designing clinical studies and would provide
a rationale for including a missense control.
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The Phase 1 study discussed in Chapter 2 demonstrated XIAP mRNA knock down of
82% and this coincided with an apparent clinical response to AEG35156 (147). In
the same patient cleaved PARP and active caspase 3 are associated with reduced
XIAP levels in lymphocytes confirming the mechanism of cell death was apoptosis.
However, it is still possible that any oligonucleotide could have decreased XIAP
levels and caused cell death by apoptosis, as again there was no missense control
included in the study.
The ethics and practicality of including a missense control in Phase 1 trials are
controversial as it would not be expected to benefit the patient and there would also
be additional development costs, as separate toxicology would be required for the
missense compound. An alternate strategy may be to analyse samples from other
antisense phase 1 trials for decreased XIAP to assess whether this is a class effect of
all antisense compounds; a BCL2 antisense oligonucleotide is in clinical trial (148).
In the laboratory, I used a different strategy to overcome the difficulties associated
with the non-specific affects of antisense, by developing a stable colorectal cancer
HCT116 cell line model incorporating short hairpin RNA targeting XIAP. This
allowed potential combination regimens to be evaluated using XIAP down regulation
in conjunction with known cytotoxic agents. XIAP is down regulated at the mRNA
(82-93%) and protein levels (67-89%) in this model and knock down is maintained
over at least 4 weeks; 79-85% at mRNA and 63-90% at protein level. The down
regulation is also similar to levels which were achieved clinically (82% at the mRNA
level) with antisense targeted to XIAP (147).
The isogenic nature of the short hairpin expressing cells was confirmed using
microarray to identify any compensatory genetic changes. Compensatory changes
had been observed in the XIAP knock out mouse (76) where CIAP1 and CIAP2
proteins were found to be up regulated. The microarray data confirmed down
regulation of XIAP at early (4.3 fold) and late (2.4 fold) passage although some of
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the down regulation was lost over time. The microarray data correlated well with
qRT-PCR data, therefore validating the newer technique. There were no
compensatory changes in genes currently documented to have an association with
XIAP, other members of the bcl-2 family, the extrinsic pathway or the other six IAP
family members. Therefore a colorectal cancer model has been developed using
isogenic cell lines which differ only in the XIAP status at clinically relevant levels.
The in vitro characterisation of these stable knock down cell lines show differences
in cell growth, plating efficiency and morphology in the XIAP deficient cells
compared to their luciferase expressing controls. It is possible that further functions
of XIAP exist which have not yet been clarified, for example XIAP binds to Chkl
implying a role in cell cycle (143) and another member of the IAP family, survivin
also has a role in cell division (58). In addition, the enhanced cytotoxicity seen with
taxanes following XIAP knockdown would be consistent with the differences in
morphology and cell growth being related to the mitotic spindle and future studies
are required to investigate this hypothesis.
In vitro cytotoxicity experiments with the XIAP deficient cell lines demonstrated a 2-
fold increase in sensitivity to rhTRAIL and a 20% increase in sensitivity to
radiotherapy. Cummins et al were able to demonstrate a greater increase in
sensitivity to TRAIL in an HCT116 XIAP knock out model (131) which further
suggests that maximising knockdown ofXIAP would be beneficial.
It may be important to distinguish between knock "down" and knock "out". A small
amount of XIAP, approximately 20%, may be enough to be functionally relevant
and, as it is the most potent caspase inhibitor (55), this argument is plausible. A
threshold may exist and greater than 80% XIAP down regulation may be required for
the balance to favour apoptosis in a colorectal cancer model.
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There was greater than 2-fold increase in sensitivity to paclitaxel and docetaxel in
vitro in the XIAP knock down studies presented here; which is similar to the effect
seen with rhTRAIL treatment. This suggests that the taxanes may have a mechanism
of drug resistance which is dependent on XIAP in HCT116 cells. This class of drug
acts by binding to tubulin and interfering with the function of the mitotic spindle
blocking cells at the metaphase-anaphase junction (35). XIAP antisense has shown
activity in prostate tumour xenografts in combination with docetaxel (40) and breast
cancer RNAi XIAP cells were sensitised to taxanes (41) suggesting a rationale for
combination of taxane therapy with XIAP knock down in a colorectal cancer model.
However, a 2 fold enhancement of activity is probably not sufficiently convincing to
encourage use in an unconventional tumour type.
Drugs commonly used in the treatment of colorectal cancer (5FU, oxaliplatin and
irinotecan) failed to show sensitisation: they all act through the intrinsic pathway.
The two compounds found to be effective in combination with XIAP down
regulation (rhTRAIL and taxanes) are associated with the extrinsic pathway (6)
(144). Further studies on the mechanism of action of taxanes may prove helpful in
identifying additional therapeutic targets. Radiotherapy is usually described in
relation to the intrinsic pathway but increasingly cross-talk between the two is
described (2), with evidence for some involvement of the extrinsic pathway via Fas
(26).
All eight short hairpin expressing cell lines have been established as in vivo
xenograft models, the L8 and X23 cell lines showing a similar growth pattern. XIAP
knockdown is maintained at the mRNA level for 26 days after implantation though
the down regulation is less than that seen in vitro. However, treatment ofX23 and L8
xenografts with docetaxel showed no significant change in growth. This may be
related to the relatively small (2 fold) increase in sensitivity seen in vitro.
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The overall aim of this project was to determine whether XIAP down regulation
alone, or in combination with other therapeutic agents, is a potential treatment for
patients with colorectal cancer. The data generated using the stable short hairpin
RNA expressing HCT116 cell line suggest that the magnitude of sensitisation to
docetaxel in vitro was insufficient for the effects to be translated to an in vivo model.
The same outcome might be anticipated for radiotherapy, although was not formally
assessed in these studies.
Further pre clinical evaluation of XIAP as a target might be relevant to colorectal
cancer, if the magnitude of the XIAP knockdown can be increased to lower further
the inhibition of apoptosis. Functional XIAP inhibitors may provide alternative
strategies; for example polyphenylurea compounds (BIR2 domain) and smac
peptidomimetics (BIR3 domain). However, difficulties with the development of
these treatments may arise due to the specificity and sensitivity of these compounds.
Additional challenges will also arise in assessing the pharmacodynamic effect as one
advantage of antisense is the simplicity of its biomarker - a decrease in XIAP levels.
Therefore, the clinical development of AEG35156 should focus on alternative
disease types. In the phase 1 clinical trial, efficacy was demonstrated in patients with
refractory breast cancer and non-Hodgkin's lymphoma. During the phase I trial, the
dose of 96mg/m2/day was identified for further phase II evaluation as a seven day
continuous intravenous infusion. However, the dose limiting toxicity of transaminitis
may be overcome by shortening the duration of the intravenous infusion. Data are
awaited from an ongoing clinical trial of infusion over 3 days to see whether this is
feasible and an appropriate PD effect is achieved. Shorter still infusion regimens over
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